Age-related macular degeneration treatment

ABSTRACT

This invention is directed to an RNA interference (RNAi) agent and the use of that RNAi agent to treat Age-related Macular Degeneration, as well as pharmaceutical compositions containing the RNAi agents of the invention. The RNAi agent is a DNA-directed RNA interference (ddRNAi) agent (being an RNA molecule), together with an expression cassette or construct to express that agent in a cell (including in vivo), for inhibiting, preventing or reducing expression of an AMD associated gene. Preferably that AMD associated gene is one that is associated with wet AMD.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a Continuation of U.S. patent application Ser. No.14/759,401, filed Jul. 6, 2015, (allowed), which is the National Stageof International Patent Application of PCT/AU2014/000007, filed Jan. 8,2014, which claims the benefit of U.S. Provisional Patent ApplicationSer. No. 61/750,086, filed Jan. 8, 2013, each of which is herebyincorporated by reference in its entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically in ASCII format and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Apr. 19, 2018, isnamed 40442US_CRF_SequenceListing.txt and is 116,002 bytes in size.

FIELD OF THE INVENTION

This invention is directed to an RNA interference (RNAi) agent and theuse of that RNAi agent to treat Age-related Macular Degeneration, aswell as pharmaceutical compositions containing the RNAi agents of theinvention.

BACKGROUND OF THE INVENTION

Age related macular degeneration (AMD) is the leading cause ofirreversible vision loss in the United States and many otherindustrialised countries. “Dry” AMD is the most common type of maculardegeneration and affects 90% of the people who have the condition. Thedry form is characterized by the formation of drusen within the macula,a specialized structural region of the retina which capture the lightthat enters the eye. Typically, drusen is formed under the retinalpigment epithelial (RPE) cells and its presence is thought to lead toatrophy of photoreceptors due to a breakdown or thinning of the RPElayer of that supports the photoreceptor cells. It is also thought thatpersistence of drusen within the retina leads to a persistentinflammatory reaction and results in a cascade of secondary responsesthat eventually can lead to wet AMD.

The “wet” form of AMD is characterized by an abnormal outgrowth of bloodvessels from the vasculature situated behind the retina in a processthat is often referred to as choroidal neovascularization (CNV). Whilenot as prevalent as the dry form, it has a more rapid onset and is moresevere phenotype, often leading to reduction of a substantial portion ofthe visual field.

The current standard of care for wet AMD is Ranibizumab (RAN), amonoclonal antibody fragment with strong affinity to the vascularendothelial growth factor-A (VEGF-A), a molecular moiety secreted fromcells and known to cause the formation or growth of nascent bloodvessels. RAN binds to and inhibits the biologic activity of VEGF-A,thereby preventing the interaction of VEGF-A with its receptors (VEGFR1and VEGFR2) on the surface of endothelial cells. This results in areduction in endothelial cell proliferation, less vascular leakage, anda reduction in new blood vessel formation characteristic of CNV.

The ocular half-life of RAN, however, is only nine days followingintravitreal injection, thus therapeutic doses must be administeredmonthly to patients to remain effective at suppressing vascularproliferation. Although useful at stabilizing visual acuity in nearly95% of patients, improved vision was noted in only 29%-40% of patients.RAN acts as a molecular sponge to mop-up secreted VEGF-A. Inefficienciesin this process may be one reason why vision is only stabilized, notimproved in most patients. In other words, it treats the symptoms butnot the cause.

The principal drawback with existing monoclonal antibody wet AMDtherapies is the requirement for frequent, continuous treatment,typically involving monthly injections into the eye. Combined with arapidly aging population and correspondingly low numbers of clinicianswho are qualified to administer intravitreal injections, application ofthis therapy This has placed enormous strain on healthcare systems. Thusthere is clearly a need for longer lasting treatments and/or treatmentsthat can reverse the symptoms. Alternative treatments for wet AMD havebeen similarly unsatisfactory, also as a result of their frequency ofadministration, but as well as their side effects or poor efficacy.

One of the newer drugs to commence clinical trials is that of the VEGFTrap Eye (VTE) which incorporates the second binding domain of theVEGFR-1 receptor and the third domain of the VEGFR2 receptor 1. Byfusing these extracellular protein sequences to the Fc segment of ahuman IgG backbone, developers have created a chimeric protein with avery high VEGF binding affinity (Stewart M W. Br J Ophthalmol (2012).doi:10.1136/bjophthalmol-2011-300654). As well as binding all isomers ofthe VEGF-A family, it also binds VEGF-B and placental growth factor.

Given the fact that the chimera protein still has a relatively shorthalf-life, VTE however must still be regularly administered—every 2months.

AAV2-sFLT01 is a gene therapy vector that expresses a modified solubleFlt1 receptor coupled to a human IgG1 Fc. As a high affinity VEGFbinding protein, AAV2-sFLT01 functions to neutralize the pro-angiogenicactivities of VEGF for treatment of wet AMD via an intravitrealinjection. (Wasworth et al. Molecular Therapy vol. 19 no. 2 Feb. 2011;326-334). The use of an AAV vector is expected to ensure long-termexpression, lasting for many months or even years, from a singleinjection. However, in order to accommodate the sFLT01 and IgG1 HeavyChain Fc fusion protein, single stranded AAV must be used, which in turnrequires high quantities of vector for efficient transduction and thusincreases the risk of an immune response to the viral capsid proteins.Moreover, a high prevalence of the normal adult population has beenexposed to serotype 2 variant of AAV, and may have pre-existing immunityagainst it.

The molecule PF-04523655 is a 19 nucleotide siRNA that inhibits theexpression of the hypoxia-inducible gene RTP801 (Nguyen et al.Ophthalmology. 2012 September; 119(9):1867-73). In clinical studiesconducted to date, it has been found to prevent neovascularization andvessel leakage, although does so via a different pathway than VEGF. Ithas been demonstrated that the siRNA only persists in the eye forseveral weeks, meaning that like so many of the other existing anddeveloping therapies, patients will require regular intravitrealinjections for treatment. A failure to do so with many treatments hasseen a continued loss of visual acuity, and a progression ofdegeneration.

More generally, previous siRNA-based approaches for treating andmanaging wet AMD have failed. Although initial pre-clinical experimentalresults were encouraging, it was subsequently demonstrated that mode ofaction of these molecules was not through a sequence specific RNAi-basedmechanism, but rather through induction of a non-specific interferonresponse mediated by the interaction of siRNAs with Toll-like receptorTLR3 (Kleinmann et al 2008). Toll-like receptors are transmembraneproteins that play a key role in the innate immune system. Oftenpositioned on either the cell surface or on intracellular vesicles suchas the endosome, some family members of this family recognize doublestranded RNA, not normally present in the endogenous cell, as foreignsubstance and triggers a cascade of molecule responses. This leads tointerferon activation, which has a transitory therapeutic effect inmouse models. However interferon has a much lower efficacy in humanswhich explains the poor efficacy of this treatment in human clinicaltesting.

Retinostat is an equine infectious anaemia virus (EIAV) based lentivirusvector expressing angiostatin and endostatin, both of which arenaturally occurring angiogenesis inhibitors in the ocular compartment.Endostatin blocks VEGF signalling, reduces vascular permeability,decreases cell matrix adhesion and promotes endothelial cell apoptosis.Angiostatin prevents endothelial cell proliferation and migration. Thegenes are delivered via a subretinal injection and inhibit the formationof new blood vessels. Sub-retinal delivery however requires an intensivesurgical procedure, which, unlike intravitreal delivery, does not lenditself to outpatient treatments or treatment at a local doctor.

Despite the large amount of development activity in the field of AMDtherapeutics, and wet AMD in particular, there remains a need to createmore effective therapies that are also patient friendly with respect toside effects, the mode of treatment and the frequency thereof. Thisinvention is directed to a RNA interference (RNAi) agent and the use ofthat RNAi agent to manage and treat wet AMD in individuals.

The RNAi pathway is initiated by the enzyme Dicer, which cleavesdouble-stranded RNA (dsRNA) molecules into short fragments (commonlyreferred to as siRNAs) of ˜20-25 nucleotides. One of the two strands ofeach fragment, known as the guide strand or active strand, is thenincorporated into the RNA-induced silencing complex (RISC) throughbinding to a member of the Argonaute protein family. After integrationinto the RISC, the guide strand base-pairs with its target mRNA and isthought to either inhibit a target by inhibiting translation (bystalling the translational machinery) and/or inducing cleavage of themRNA, thereby preventing it from being used as a translation template.

While the fragments produced by Dicer are double-stranded, only theguide strand, directs gene silencing. The anti-guide strand (referred tocommonly as a passenger strand, carrier strand or * strand) isfrequently degraded during RISC activation (Gregory R et al., 2005).RISC assembly is thought to be governed by an enzyme that selects whichstrand of a dsRNA Dicer product is loaded into RISC. This strand isusually the one whose 5′ end is less tightly paired to its complement.There also appears to be a clear bias for A, and to a lesser extent U,at the 5′ position to facilitate binding to some Argonaute proteins(Schwarz D S et al., 2003; Frank F et al., 2010).

The present invention seeks to overcome the problems associated withother therapies as already discussed above, while overcoming theprevious challenges faced by RNAi therapeutics in this field.

Reference to any prior art in the specification is not, and should notbe taken as, an acknowledgment or any form of suggestion that this priorart forms part of the common general knowledge in Australia or any otherjurisdiction or that this prior art could reasonably be expected to beascertained, understood and regarded as relevant by a person skilled inthe art.

SUMMARY OF THE INVENTION

There is an unmet need for long term therapy for AMD, and in particular,wet AMD. It has been discovered by the current inventors that particularRNAi constructs have the ability to down-regulate the expression ofgenes associated with the development of AMD (collectively referred toas ‘AMD associated genes’). This in turn can slow the progression of AMDand the accompanying vision loss, and in some instances, result in animprovement in visual acuity. By utilising RNAi technology to achievelong term suppression of those target sequences, together with the useof a vector delivery vehicle that directs the RNAi agent to the targetcells in a non-invasive manner, this need can be met and it can be metin a patient convenient and friendly manner. Moreover, because RNAagents expressed from DNA directed RNAi (ddRNAi) constructs are producedin the nucleus and do not interact with Toll-like receptors on eitherthe cell surface or within the endomal compartment, ddRNAi agents can beproduced without activating an interferon response via the TLRs.

In one aspect of the invention, there is provided a DNA-directed RNAinterference (ddRNAi) agent (being an RNA molecule), and an expressioncassette or construct to express that agent in a cell (including invivo), for inhibiting, preventing or reducing expression of one or moretarget sequences in an AMD associated gene, preferably a wet AMDassociated gene, where the agent comprises

-   -   an effector sequence (described further below) of at least 17        nucleotides in, and    -   an effector complement sequence        wherein the effector sequence is complementary or substantially        complementary to one or more target regions in a transcript of        the one or more target sequences.

The target region can be selected from the group consisting of any 10 ormore contiguous nucleotides within a transcript of a target sequenceselected from any one or more of SEQ ID NOS: 1-39. The effectorcomplement sequence is substantially complementary to the effectorsequence such that it will tend to anneal so as to form a doublestranded RNA segment.

The effector sequence is directed to a target region within a transcriptof a target sequence of a target gene. Thus the effector sequence is‘directed to’ a target region by being substantially complementary (as‘substantial complementarity’ is defined below) in sequence to atranscript from a target gene containing the target region. An RNAiagent, such as a ddRNAi agent, having a double-stranded portioncontaining the effector sequence, can therefore “inhibit expression of atarget gene sequence” by virtue of the target gene sequence containingthe target region. Accordingly, within a cell having an AMD associatedgene, the RNAi agent is capable of inhibiting expression of a targetgene sequence because the sequence of the effector (as ‘effector’ isdefined below) is substantially complementary to (at least) a region ofthe mRNA target sequence of the target gene. This can be illustrated byconsidering the following random, hypothetical short sequence:

-   -   5′GGCATTGCG3′—target region within target sequence    -   5′GGCAUUGCG3′—transcript of target sequence    -   3′GUAACG5′—effector sequence, which is substantially        complementary to the target region in the transcript of the        target sequence.

Typically, a target region is a region of nucleic acid sequence withinthe mRNA of a gene that is intended to be silenced or to have itsexpression (at the level of transcription or translation) reduced,inhibited or prevented.

As can be seen in the explanatory comparison above, ‘substantialcomplementarity’ between the effector sequence and the effectorcomplement sequence can be 100% complementarity. However as moreparticularly explained and defined further below, substantialcomplementarity can be 80% to 100% complementary. So in an effectorsequence having a length of, for example, 20 nucleotides, the effectorsequence is substantially complementary to the effector complementsequence if 17 of the 20 nucleotides are complementary ie 85%complementarity. Moreover, usually one end of the double strandedsegment will be linked by a loop sequence so as to form a ‘hairpin’shaped structure referred to as shRNA. This is also known as an‘interrupted inverted repeat’ structure, as the DNA encoding such an RNAsequence contains an inverted repeat of the region of the target genethat is transcribed to the effector sequence, interrupted by a stufferor spacer sequence encoding the loop.

The concept of substantial complementary described in the paragraphabove applies equally to the substantial complementarity between theeffector sequence and the target sequence where substantialcomplementarity can be 80% to 100% complementarity. That is, if thetarget region within a target sequence is 20 nucleotides long, and theeffector sequence is 20 nucleotides long, then the effector sequence mayhave, for example, 16, 17, 18 or 20 nucleotides that are complementarywith the target, equating to 80%, 85%, 90% and 100% complementarityrespectively.

In both situations, one will appreciate that substantial complementaritymay not equate to a whole number. For example, at least 85%complementarity to a sequence of 22 nucleotides would be 18.7nucleotides, so is effectively a requirement for 19 of 22 to becomplementary.

Alternatively, substantial complementarity of 80 to 100% complementarity(both in the context of substantial complementarity between the effectorand target, and effector and its complement) can be described withreference to the number of nucleotides that will not G-C/A-U base pair(except for wobble pairs as described below). There may be 1, 2, 3, 4 or5 nucleotides within the complementary region between the 2 RNAs thatare not themselves complementary with a nucleotide on the other strandwhen considering at least 80% complementarity across a nucleotidesequence. As to whether there can be 1, 2, 3, 4 or 5 nucleotides that donot base pair is dependent on the length of the relevant sequence. Forexample, if the effector sequence is 17 nucleotides long, it cannot have5 nucleotides that will not base pair, as this would equate to only 71%complementarity. In a 17 nucleotide sequence, there must becomplementarity between 14 of the 17 nucleotides for at least 80%complementarity.

In a preferred embodiment of the invention, the double stranded regionformed by the effector sequence and its complement is expressed as partof a microRNA (miRNA) structure similar to the structure of endogenousmiRNAs which are a natural substrate for endogenous RNAi processingpathways. Processing of double stranded RNAs expressed from ddRNAiconstructs can be imprecise, and can result in toxicity. McBride et al.(2008) designed “artificial miRNA” constructs which expressed sequencesfrom the base and loop of endogenous miRNAs, and suggested that moreprecise processing of expressed shRNAs from the miR-backbone led toreduced toxicity from the constructs. Wu et al. (2011) showed thatmismatched duplexes (containing mismatches in the passenger strand)sometimes showed increased silencing activity, due possibly to theirgreater structural resemblance to endogenous miRNAs.

In one aspect of the invention, there is provided a ddRNAi agent and anexpression cassette to express that agent in a cell, for inhibiting,preventing or reducing expression of an AMD associated gene, preferablya wet AMD associated gene, where the agent comprises

-   -   an effector sequence of at least 17 nucleotides in length        complementary to or substantially complementary to one or more        target regions in a transcript of a target region, and an        effector complement sequence        wherein the effector sequence and the effector complement        sequence are expressed within a miRNA structure. The target        region may be selected from the group consisting of any 10 or        more contiguous nucleotides within a transcript of a sequence        selected from any one or more of SEQ ID NOS: 1-39.

In some forms of the invention, the agent has more than one effectorsequence. Multiple effectors may target the same region of a wet AMDassociated gene (typically variants of the same region), differentregions of a wet AMD associated gene, more than one wet AMD associatedgene, or a combination of all of the above.

RNAi agents, such as ddRNAi agents, can contain 2 or 3 or more effectorsequences. As explained above, the ddRNAi agent comprises an effectorcomplement sequence for each effector sequence, thus formingeffector-effector complement pairs (ie a first effector-first effectorcomplement pair, a second effector-second effector complement pair,etc). These pairs may be, but need not be, contiguous to one another, aslong as the RNAi agent can fold so as to permit each pair to anneal.Various other considerations suggest one order or another of theeffectors and effector complements along the length of the RNAi agent.In addition, as would be understood by one skilled in the art, and asillustrated in the Figures, any particular effector sequence may beswapped in position with its complement in the agent. The importantfeature, as exemplified in the various embodiments below, is that theeffector sequence is able to anneal with its complement to form a doublestranded region. For example:

-   -   ddRNAi agent comprising, in a 5′ to 3′ direction, a first        effector sequence; a second effector sequence; second effector        complement sequence; and a first effector complement sequence;    -   a ddRNAi agent comprising, in a 5′ to 3′ direction, a first        effector sequence; a second effector sequence; a third effector        sequence; a third effector complement sequence; a second        effector complement sequence; and a first effector complement        sequence;    -   a ddRNAi agent comprising, in a 5′ to 3′ direction, a first        effector; a first effector complement sequence; a second        effector sequence; and a second effector complement sequence;    -   a ddRNAi agent comprising, in a 5′ to 3′ direction, a first        effector sequence; a first effector complement sequence; a        second effector sequence; a second effector complement sequence;        a third effector sequence; and a third effector complement        sequence;    -   a ddRNAi agent comprising, in a 5′ to 3′ direction, a first        effector sequence; a second effector sequence; a loop sequence        of 2 to 100 non-self-complementary nucleotides; a second        effector complement sequence; and a first effector complement        sequence;    -   a ddRNAi agent comprising, in a 5′ to 3′ direction, a first        effector sequence; a loop sequence of 2 to 100        non-self-complementary nucleotides; a first effector complement        sequence; a sequence of 2 to 100 non-self-complementary        nucleotides; a second effector sequence; a loop sequence of 2 to        100 non-self-complementary nucleotides; and a second effector        complement sequence;    -   a ddRNAi agent comprising, in a 5′ to 3′ direction, a first        effector sequence; a loop sequence of 2 to 100        non-self-complementary nucleotides; a first effector complement        sequence; a spacer sequence of 2 to 100 non-self-complementary        nucleotides; a second effector sequence; a loop sequence of 2 to        100 non-self-complementary nucleotides; and a second effector        complement sequence;    -   a ddRNAi agent comprising, in a 5′ to 3′ direction, a first        effector sequence; a first effector complement sequence; a        spacer sequence of 2 to 100 non-self-complementary nucleotides;        a second effector sequence; a second effector complement        sequence; a spacer sequence of 2 to 100 non-self-complementary        nucleotides; a third effector sequence; and a third effector        complement sequence.

The non-self-complementary nucleotides act as loop sequences whenlocated between an effector and its complement, and as spacer sequenceswhen located between the complement of one effector sequence, and thenext effector sequence. In each of these embodiments, the effectorsequence and its complement, as well as any additional sequence such asa sequence of 2 to 100 non-self-complementary nucleotides, is expressedwithin or part of a miRNA structure.

In particular forms of each of the embodiments described above, eacheffector sequence is at least 17 nucleotides in length, preferably 17 to30 nucleotides in length, and more preferably 17 to 21 nucleotides inlength, and comprises a nucleotide sequence selected from the groupconsisting of any 10 or more contiguous nucleotides from a sequence fromany one of SEQ ID NOS: 40-78. The effector sequences may all be thesame, or may all be different, or may be a combination, e.g. 2 effectorsequences of at least 10 contiguous nucleotides of SEQ ID NO:47 and oneeffector sequence of at least 10 contiguous nucleotides of SEQ ID NO:56.

Preferably, the effector sequence is selected from the group consistingof any contiguous 11, 12, 13, 14, 15 or 16 nucleotides within any one ofSEQ ID NOS: 40-78, and preferably 17 or more contiguous nucleotideswithin any one of SEQ ID NOS: 40-78 and most preferably 17 to 21contiguous nucleotides within any one of SEQ ID NOS: 40-78. Typically,the effector complement will be the same length, or about the samelength (ie ±15% nucleotide length, or 1 to 3 nucleotides depending onthe total length) as its corresponding effector sequence.

In particular embodiments the effector sequence of the ddRNAi agentconsists of, or consists essentially of, a nucleotide sequence selectedfrom the group consisting of any one of SEQ ID NOS: 40-78 inclusive. Inthese embodiments, a ddRNAi agent SEQ ID NOS: 40-78 as well asadditional nucleotides or other chemical modifications would “consistessentially of” SEQ ID NOS: 40-78 as long as it exhibits activity forinhibiting, reducing or preventing the expression of the target gene, asmay be determined in accordance with the assays described below.Similarly, an RNAi agent “consists essentially of” one of SEQ ID NOS:40-78 where it is shorter than the corresponding SEQ ID as long as itexhibits activity for inhibiting, reducing or preventing the expressionof the target gene, as may be determined in accordance with the assaysdescribed below.

In alternative embodiments, the dsRNA is comprised of 2 separate RNAstrands that are annealed to form a duplex. That duplex may then beembedded in a miRNA backbone.

ddRNAi agents may be expressed from a DNA expression cassette insertedinto any suitable vector or ddRNAi construct. Accordingly, in aspects ofthe invention there is provided a ddRNAi expression cassette comprising(in no particular order):

-   -   one or more promoter sequences    -   one or more DNA sequences that encode for one or more effector        sequences, preferably being DNA sequences that encode for any 10        or more and preferably any 17 or more contiguous nucleotides        within a sequence from any one of SEQ ID NOS: 40-78,    -   one or more DNA sequences that encode for one or more effector        complement sequences        and optionally    -   one or more terminator sequences    -   one or more DNA sequences that encode for spacer sequences, loop        sequences, or both; and    -   one or more enhancer sequences.

In some embodiments, one promoter is operably linked to multipleeffector-encoding regions such that a ddRNAi agent with multipleeffector sequences is produced. In alternative embodiments, where eacheffector-encoding region is operably linked to its own promoter,multiple ddRNAi agents are produced from a single expression cassette.In constructs where there are multiple promoters, these may be all thesame or different. Preferred promoters are pol III promoters such as U6and H1; pol II promoters such as the RPE cell specific promoter RPE-65(Boye et al. 2012) and VMD2 (Zhu et al. 2010), and choroidendothelial-specific promoters FLT-1 or ICAM2 can also be used to driveexpression of ddRNAi constructs.

In embodiments where the effector sequence and its complement, areexpressed within a miRNA structure, the ddRNAi expression cassetteadditionally comprises sequences that encode for the miRNA structurereferred to herein as miRNA encoding (ME) sequences. The ME sequencesmay also encode for loop sequences.

There is also provided ddRNAi expression constructs, into which theddRNAi expression cassettes are inserted for expression. In addition,when the vector backbone of the construct is compatible with a deliverysystem, the ddRNAi expression constructs are also delivery constructs. Aparticularly preferred delivery construct is a viral vector, such as amodified adeno-associated virus (AAV) vector (Petrs-Silva et al. 2011)that allows delivery of ddRNAi expression cassettes to appropriate cellsdeep in the retina following intravitreal injection. Use of a modifiedAAV to deliver an expression construct that produces the therapeuticddRNAi agent from within the cell avoids an interferon response oftencaused by direct interactions of nucleic acids with surface-expressedtoll-like receptor 3. This is hypothesised to be the reason for a numberof failures of siRNA-based ocular drugs in clinical trials.

Accordingly, in this embodiment there is provided a ddRNAi expressionconstruct comprising a ddRNAi expression cassette for expressing addRNAi agent for inhibiting expression of one or more target sequencesin an AMD associated gene, the expression cassette comprising (in noparticular order)

-   -   one or more promoter sequences    -   one or more DNA sequences that encode for one or more effector        sequences,    -   one or more DNA sequences that encode for one or more effector        complement sequences;    -   and optionally    -   one or more terminator sequences    -   one or more DNA sequences that encode for loop sequences, spacer        sequences or both,    -   one or more enhancer sequences,        wherein the construct is a viral vector delivery vehicle.

Preferably the expression cassette further comprises ME sequence so thatthe ddRNAi agent is expressed as part of or within a miRNA structure.

In one embodiment, the expression cassette of the viral vector deliveryconstruct comprises one DNA sequences that encodes a first effectorsequence of any 10 or more contiguous nucleotides within 5′UAUGUGGGUGGGUGUGUCUAC 3′ of the AMD-associated gene VEGF-A (SEQ IDNO:47).

In a further embodiment, the expression cassette of the viral vectordelivery construct comprises two DNA sequences that encode a firsteffector sequence of any 10 or more contiguous nucleotides within 5′UGUAACAGAUGAGAUGCUCCA 3′ of the AMD-associated gene VEGRF-2 (SEQ IDNO:56) and a second effector sequence of any 10 or more contiguousnucleotides within 5′ UAUGUGGGUGGGUGUGUCUAC 3′ of the AMD-associatedgene VEGFA (SEQ ID NO:47).

In yet another alternative embodiment, the expression cassette of theviral vector delivery construct comprises three DNA sequences thatencode a first effector sequence of any 10 or more contiguousnucleotides within 5′ AAGUAGCCAGAAGAACAUGGC 3′ of the AMD-associatedgene VEGRF-2 (SEQ ID NO:52); a second effector sequence of any 10 ormore contiguous nucleotides within 5′ UUAUAGAAAACCCAAAUCCUC 3′ of theAMD-associated gene CFB (SEQ ID NO:78); and a third effector sequence ofany 10 or more contiguous nucleotides within 5′ UAGCUGAAGCCCACGAGGUCC 3′of the AMD-associated gene PDGFR-β (SEQ ID NO:63).

The invention also provides for siRNA agents that comprise a sequence ofat least 17 nucleotides in length selected from the group consisting ofany 10 or more contiguous nucleotides within a sequence from any one ofSEQ ID NOS: 40-78 and a sequence complement with which the sequenceforms a duplex, and that are capable of inhibiting expression of a wetAMD associated gene.

In accordance with some embodiments, there is provided a method ofinhibiting the expression of an mRNA or polypeptide encoded by an AMDassociated gene in a subject comprising administering to the subject acomposition of the invention comprising a ddRNAi agent that consistsessentially of or consists of a nucleotide sequence selected from thegroup consisting of any one of SEQ ID NOS: 40-78 and sequences that varyfrom SEQ ID NOS: 40-78 by 1, 2, 3, 4 or 5 nucleotides. A ddRNAiexpression cassette or ddRNAi expression construct for expressing theddRNAi agent may also be administered.

In another embodiment the invention provides a composition for thetreatment of AMD in a subject, preferably wet AMD, or treatment of otherdiseases that are caused by inappropriate vascularisation within theretina, comprising as an active ingredient a ddRNAi agent, ddRNAiexpression cassette or ddRNAi expression construct of the invention forinhibiting, preventing or reducing expression of one or more targetsequences in an AMD associated gene.

In another embodiment the invention provides a pharmaceuticalcomposition comprising an effective amount of a ddRNAi agent, ddRNAiexpression cassette or ddRNAi expression construct of the invention as amain ingredient for inhibiting, preventing or reducing expression of oneor more target sequences in an AMD associated gene. The composition maybe used for example for the treatment of AMD in a subject, preferablywet AMD, or treatment of other diseases that are caused by inappropriatevascularisation within the retina. In some embodiments, the compositionfurther comprises a pharmaceutically acceptable carrier or diluent.

In another embodiment the invention provides a composition for thetreatment of AMD in a subject, preferably wet AMD, or treatment of otherdiseases that are caused by inappropriate vascularisation within theretina, comprising as an active ingredient a ddRNAi agent, ddRNAiexpression cassette or ddRNAi expression construct of the invention forinhibiting, preventing or reducing expression of one or more targetsequences in an AMD associated gene.

In another embodiment the invention provides a composition forinhibiting, preventing or reducing expression of one or more targetsequences in an AMD associated gene comprising a ddRNAi agent, ddRNAiexpression cassette or ddRNAi expression construct of the invention foruse in the treatment of wet AMD in a subject. In some embodiments, thecomposition further comprises a pharmaceutically acceptable carrier ordiluent.

In another embodiment, the invention provides a ddRNAi agent, ddRNAiexpression cassette or ddRNAi expression construct for inhibiting,preventing or reducing expression of one or more target sequences in anAMD associated gene in the preparation of a medicament for the treatmentof AMD in a subject. Preferably the medicament is for wet AMD.

In another embodiment the invention provides an AMD treatmentcomposition comprising an effective amount of a ddRNAi agent, ddRNAiexpression cassette or ddRNAi expression construct of the invention forinhibiting, preventing or reducing expression of one or more targetsequences in an AMD associated gene as a main ingredient, optionallywith a pharmaceutically acceptable carrier or diluent.

The invention also provides a method for treating or delaying theprogression of diseases that are caused by inappropriate vascularisationwithin the retina in a subject, comprising administering to the subjecta ddRNAi agent, ddRNAi expression cassette or ddRNAi expressionconstruct or composition of the invention for inhibiting, preventing orreducing expression of one or more target sequences in an AMD associatedgene, thereby reducing the severity of AMD.

Yet a further aspect of the invention provides a method for reducing theprogression of AMD in a subject, preferably wet AMD, comprisingadministering to the subject a ddRNAi agent, ddRNAi expression cassetteor ddRNAi expression construct or composition of the invention forinhibiting, preventing or reducing expression of one or more targetsequences in an AMD associated gene, thereby reducing the severity ofAMD.

In each of the methods of the invention, the ddRNAi agent, ddRNAiexpression cassette or ddRNAi expression construct or composition of theinvention is preferably delivered to the subject's eye/s by intravitrealinjection or subretinal injection.

In a further aspect, the present invention provides a kit of partsincluding (a) a ddRNAi agent, ddRNAi expression cassette or ddRNAiexpression construct or composition of the invention and (b) apharmaceutically acceptable carrier or diluent.

In certain embodiments an RNAi agent or pharmaceutical composition ofthe invention may be provided in the form of a device, disposable orreusable, including a receptacle for holding the RNAi agent orpharmaceutical composition. In one embodiment, the device is a syringe,preferably a syringe suitable for intravitreal injection or subretinalinjection. The RNAi agent or pharmaceutical composition may be providedin the device in a state that is ready for use or in a state requiringmixing or addition of further components.

Although the invention finds application in humans, the invention isalso useful for veterinary purposes. The invention is useful for thetreatment of AMD or other diseases caused by inappropriatevascularisation in domestic animals such as cattle, sheep, horses andpoultry; companion animals such as cats and dogs; and zoo animals.

BRIEF DESCRIPTION OF THE DRAWINGS/FIGURES

FIG. 1A-G illustrates some of the ddRNAi agent structures of theinvention.

FIG. 2: A. Map of pSilencer (Invitrogen). This expression cassettecontains the human U6 promoter (black arrow) and was designed to expressshRNA sequences cloned into this vector as BamH I/Hind III fragments. B.A generalized map showing the schematic layout of a BamH I/Hind IIIshRNA fragment designed to silence AMD associated genes. The positionsof BamHi/Hind III restriction sites are shown; the white arrows denotesequences from the 5′ stem of miR30a, a sequence derived from the loopof mir30a and the 3′ stem of miR30a. The grey arrow represents thepredicted passenger strand and the black arrow the predicted guidestrand. The relative positioning of the predicted guide strand and thepredicted passenger strand may be interchangeable. The black linedenotes a pol III termination signal. C. DNA sequence of the miR-8fragment, which potently silences VEGF-A, is shown and corresponds toSEQ ID NO: 98. The lowercase letters denote restriction sites,mir30a-related sequences and pol III terminator sequences. Theunderlined sequences are derived from the base of human miR30apre-cursor RNA (both 5′ and 3′); sequences in italics are derived fromthe loop sequences of miR30a. The upper case sequences indicate thepredicted passenger strand sequence, the bold uppercase sequences denotethe predicted effector sequence (SEQ ID NO: 47). D. Predicted RNAsecondary structure of miR-8, determined using the M-fold program (SEQID NO:147); the predicted Dicer and Drosha processing sites areindicated by arrows.

FIG. 3: A. Map of pGL3-VEGFA-sense reporter. The plasmid encodes fireflyluciferase (Fluc+) driven by the SV40 promoter (grey arrows) and aeukaryotic transcriptional terminator. A portion of the non-codingstrand of the VEGF-A gene was inserted into the 3′ UTR of FLuc+transcriptional unit using Xba I and Fse I restriction sites present inthe 3′UTR of the parent plasmid (pGL3; Promega). This plasmid was usedto quantify inhibitory activity of the passenger strand of miR-2 in dualluciferase assays. B. Map of pGL3-VEGFa-antisense reporter, features areshown as in FIG. 3A. The corresponding portion of the VEGF-A gene usedin FIG. 3A was inserted into the 3′ UTR of FLuc+ transcriptional unitusing Xba I and Fse I restriction sites, but used the coding strand ofthe VEGF-A gene. This plasmid was used to quantify inhibitory activityof the effector strand of miR-2 in dual luciferase assays.

FIG. 4: A. The graph shows the percent inhibition of VEGF-A expressiondetermined using dual luciferase assays; activities against both senseand antisense targets in sensor constructs are shown (n=3±SD). B. Thegraph shows percent inhibition of VEGF-A mRNA levels determined by qRTPCR in HEK293T cells co-transfected with either miR-2, miR-5 and miR-8along with a full length cDNA that expresses the full length VEGF-Aprotein. Percent inhibition is calculated to untransfected cells andempty vector controls (pSilencer and an empty U6 expression cassette).C. The graph shows levels of VEGF-A mRNA and protein in ARPE-19 cellsthat have been transduced with an adenovirus vector expressing miR-8.Samples of RNA and protein were collected at 24, 48, 72 and 96 hourspost transduction. The triangles show intracellular levels of mature,processed miR-8 in which the loop sequences have been cleaved.

FIG. 5: A. The graph shows the percent inhibition of VEGFR2 determinedusing firefly luciferase reporters as previously described; activitiesagainst both sense and antisense reporter constructs are shown (n=3±SD).B. The graph shows percent inhibition of VEGFR2 mRNA levels determinedby RT QPCR in HEK203T cells that were co-transfected with miR-V-2,miR-V-3, miR-V-7 or miR-V-10 and a plasmid expressing a full length cDNAto VEGFR2. Percent inhibition was calculated as mRNA remaining ascompared to empty vector controls (pSilencer; Invitrogen and anunrelated plasmid). C. Western blot analysis of cells transfected inparallel conditions as in 5B and showing reductions in VEGFR2 (arrow).Protein extracts from HUVEC cells were run in parallel to showpositioning of VEGFR2 on the gel.

FIG. 6: A. The graph shows percent inhibition of PDGFR-β mRNA levels inHEK293T cells that were co-transfected with either miR-V-4 or miR-V-9and a plasmid expressing a full length cDNA to PDGFR-β. Percentinhibition was calculated as mRNA remaining as compared to controls(pSilencer, Invitrogen and an unrelated plasmid and an empty U6expression cassette). B. Western blot analysis of cells transfected inparallel conditions as in 6B and showing reductions in PDGFR-β (arrows).

FIG. 7: A. The graph shows the percent inhibition of CFB expressiondetermined using firefly luciferase reporters as previously described;activities against both sense and antisense reporter constructs areshown (n=3±SD). B. The graph shows percent inhibition of CFB mRNA levelsin HEK293T cells co-transfected with miR-C-1, miR-C-8 or miR-C-9 and aplasmid expressing a full length cDNA to CFB. Percent inhibition wascalculated as compared to controls (pSilencer, Invitrogen, an unrelatedplasmid and an empty U6 expression cassette). C. Western blot analysisperformed on parallel treated wells as in 7B showed reductions in CFB(arrows).

FIG. 8: A. Map of U6-miR-7. This uses the human U6 promoter (blackarrow) to drive expression of miR-7 which targets VEGF-A. The miR-7coding sequences are identical to those in FIG. 2A and are shown as awhite arrow, the positions of miR-7 passenger and miR-7 effectorsequences are shown as grey arrows. The sequence of the U6-miR-7fragment is listed as SEQ ID NO: 132. B. Map of VMD2-miR-7. This usesthe human VMD2 promoter (black arrow) to drive expression of miR-7(white arrow), which targets VEGF-A. The sequence of the VMD2-miR-7fragment is listed as SEQ ID NO: 133. C. Map of ICAM2-miR-7. This usesthe human ICAM2 promoter (black arrow) to drive expression of miR-7(white arrow), which targets VEGF-A. The sequence of the ICAM2-miR-7fragment is listed as SEQ ID NO: 134. D. Map of RPE-65-miR-7. This usesthe human RPE65 promoter (black arrow) to drive expression of miR-7(white arrow), which targets VEGF-A. The sequence of the RPE65-miR-7fragment is listed as SEQ ID NO: 135. E. Map of FLT-miR-7. This uses thehuman FLT promoter (black arrow) to drive expression of miR-7 (whitearrow), which targets VEGF-A. The sequence of the FLT-miR-7 fragment islisted as SEQ ID NO: 136.

FIG. 9: A. Map of U6-miR-7-miR-V-7. This uses the human U6 promoter(black arrow) to drive expression of miR-7-miR-V-7 which targets VEGF-Aand VEGFR2. The miR-7-miR-V-7 coding sequences are shown as a whitearrow, the positions of miR-7 passenger and miR-7 effector sequences andmiR-V-7 passenger and miR-V-7 effector sequences are shown as greyarrows. The sequence of the U6-miR-7 fragment is listed as SEQ ID NO:137. B. Map of VMD2-miR-7 miR-V-7. This uses the human VMD2 promoter(black arrow) to drive expression of miR-7 miR-V-7 (white arrow), whichtargets VEGF-A and VEGFR2. The sequence of the VMD2-miR-7 miR-V-7fragment is listed as SEQ ID NO: 138. C. Map of ICAM2-miR-7 miR-V-7.This uses the human ICAM2 promoter (black arrow) to drive expression ofmiR-7 miR-V-7 (white arrow), which targets VEGF-A and VEGFR2. Thesequence of the ICAM2-miR-7 miR-V-7 fragment is listed as SEQ ID NO:139. D. Map of RPE-65-miR-7 miR-V-7. This uses the human RPE65 promoter(black arrow) to drive expression of miR-7 miR-V-7 (white arrow), whichtargets VEGF-A and VEGFR2. The sequence of the RPE65-miR-7 miR-V-7fragment is listed as SEQ ID NO: 140. E. Map of FLT-miR-7 miR-V-7. Thisuses the human FLT promoter (black arrow) to drive expression of miR-7miR-V-7 (white arrow), which targets VEGF-A and VEGFR2. The sequence ofthe FLT-miR-7 fragment is listed as SEQ ID NO: 141.

FIG. 10: A. Map of U6-miR-V-7-miR-C-8-miR-P-9. This uses the human U6promoter (black arrow) to drive expression of miR-V-7-miR-C-8-miR-P-9which targets VEGFR2, CFB and PDGFR-β. The miR-V-7-miR-C-8-miR-P-9coding sequences are shown as a white arrow, the positions of miR-V-7passenger and miR-V-7 effector sequences, miR-C-8 passenger and miR-C-8effector sequences, and miR-P-9 passenger and miR-P-9 effector sequencesare shown as grey arrows. The sequence of the U6-miR-V-7-miR-C-8-miR-P-9fragment is listed as SEQ ID NO: 142. B. Map ofVMD2-miR-V-7-miR-C-8-miR-P-9. This uses the human VMD2 promoter (blackarrow) to drive expression of miR-V-7-miR-C-8-miR-P-9 (white arrow),which targets VEGFR2, CFB and PDGFR-β. The sequence of theVMD2-miR-V-7-miR-C-8-miR-P-9 fragment is listed as SEQ ID NO: 143. C.Map of ICAM2-miR-V-7-miR-C-8-miR-P-9. This uses the human ICAM2 promoter(black arrow) to drive expression of miR-V-7-miR-C-8-miR-P-9 (whitearrow), which targets VEGFR2, CFB and PDGFR-β. The sequence of the ICAM2miR-V-7-miR-C-8-miR-P-9 fragment is listed as SEQ ID NO: 144. D. Map ofRPE65-miR-V-7-miR-C-8-miR-P-9. This uses the human RPE65 promoter (blackarrow) to drive expression of miR-V-7-miR-C-8-miR-P-9 (white arrow),which targets VEGFR2, CFB and PDGFR-β. The sequence of theRPE65-miR-V-7-miR-C-8-miR-P-9 fragment is listed as SEQ ID NO: 145. E.Map of FLT-miR-V-7-miR-C-8-miR-P-9. This uses the human FLT promoter(black arrow) to drive expression of miR-V-7-miR-C-8-miR-P-9 (whitearrow), which targets VEGFR2, CFB and PDGFR-β. The sequence of theFLT-miR-V-7-miR-C-8-miR-P-9 fragment is listed as SEQ ID NO: 146.

FIG. 11: sequences referred to throughout the specification.

DETAILED DESCRIPTION OF THE EMBODIMENTS

Reference will now be made in detail to certain embodiments of theinvention. While the invention will be described in conjunction with theembodiments, it will be understood that the intention is not to limitthe invention to those embodiments. On the contrary, the invention isintended to cover all alternatives, modifications, and equivalents,which may be included within the scope of the present invention asdefined by the claims.

One skilled in the art will recognize many methods and materials similaror equivalent to those described herein, which could be used in thepractice of the present invention. The present invention is in no waylimited to the methods and materials described.

It will be understood that the invention disclosed and defined in thisspecification extends to all alternative combinations of two or more ofthe individual features mentioned or evident from the text or drawings.All of these different combinations constitute various alternativeaspects of the invention.

For purposes of interpreting this specification, the followingdefinitions will apply and whenever appropriate, terms used in thesingular will also include the plural and vice versa. In the event thatany definition set forth conflicts with any document incorporated hereinby reference, the definition set forth below shall prevail.

Definitions

As used herein, except where the context requires otherwise, the term“comprise” and variations of the term, such as “comprising”, “comprises”and “comprised”, are not intended to exclude further additives,components, integers or steps.

The term “RNA interference” or “RNAi” refers generally to a RNAdependent gene silencing process that is initiated by double strandedRNA (dsRNA) molecules in a cell's cytoplasm. The dsRNA reduces theexpression of a target nucleic acid sequence, which may be a DNA whoseRNA expression products are reduced, or an RNA, with which the dsRNAmolecule shares substantial or total homology.

By “double stranded RNA” or “dsRNA” it is meant a double stranded RNAmolecule that is capable of inhibiting expression of a target nucleicacid sequence with which it shares homology. In some embodiments thedsRNA is a hairpin or stem loop structure, with a duplex regionoptionally linked by at least 1 nucleotide, and is referred to as a“hairpin RNA” or “short hairpin RNAi agent” or “shRNA”. The duplex isformed between an effector sequence and a sequence complementary to theeffector sequence herein referred to as an “effector complement”.Typically, the effector complement will be the same length as itscorresponding effector sequence. As will be explained below, theeffector sequence is complementary to the target nucleic acid sequence.

An “effector sequence” is the nucleotide sequence that, when part of theRISC complex, binds to the target nucleotide sequence, thereby targetingthat sequence for destruction by the cell. It is analogous to the“guide” strand discussed in the background section. The effectorsequence is ‘directed to’ a target region by being complementary orsubstantially complementary in sequence to the transcript from thetarget region such that an RNA agent having a double stranded portioncontaining the effector sequence inhibits expression of the target genesequence.

The “effector complement”, which is analogous to the passenger stranddiscussed in the background is of sufficient complementarity to theeffector such that it anneals to the effector sequence. It is likelythat the effector complement will be of a similar sequence to the targetgene sequence, but does not necessarily have to be.

As already detailed in the sections above “substantially complementary”,or “substantial complementarity”, it is meant that the sequences are ofsufficient complementarity to enable hybridisation of annealing (aslater defined). Briefly, substantial complementarity as described abovemay be described in terms of:

-   -   percentage identity (being 80 to 100%) between an effector and        its complement, or between an effector and the target region of        a target sequence; or    -   number of nucleotides that are not complementary, being 1, 2, 3,        4 or 5, provided that number is consistent with the percentage        identity requirement of 80 to 100%.

Substantial complementarity therefore includes 100% complementarity, but100% complementarity may also be referred to throughout thespecification as “complementary”, or “being complementary”. A sequencecomplementary to or substantially complementary to a region of a targetgene has the degree of sequence complementarity across a contiguoustarget sequence. Generally, a double stranded RNA region of theinvention may be subjected to mutagenesis to produce single or severalnucleotide substitutions, deletions or additions. It is believed thatthis level of difference between an effector and its complement, orbetween an effector and the target region of a target sequence will notnegatively impact on the ability of the ddRNAi agent to be able toinhibit expression of the target sequence.

When the first effector sequence does have 1, 2, 3, 4 or 5 nucleotidesthat will not G-C/A-U base pair with the target sequence, it ispreferred that the differences are in the first or last 5 nucleotides ofthe first effector sequence, with only 1 or 2 nucleotide changes in thecentre portion of the effector sequence.

As noted above, substantial complementarity is intended to mean that thesequences are hybridisable or annealable. The terms “hybridising” and“annealing” (and grammatical equivalents) are used interchangeably inthis specification in respect of nucleotide sequences and refer tonucleotide sequences that are capable of forming Watson-Crick base pairsdue to their complementarity. Preferably the substantially complementarysequences are able to hybridise under conditions of medium or highstringency:

-   -   high stringency conditions: 0.1×SSPE (or 0.1×SSC), 0.1% SDS, 65°        C.    -   medium stringency conditions: 0.2×SSPE (or 1.0×SSC), 0.1% SDS,        50° C.

Alternatively, “substantially complementary” would also be understood bythe person skilled in the art to involve non-Watson-Crick base-pairing,especially in the context of RNA sequences, such as a so-called “wobblepair” which can form between guanosine and uracil residues in RNA.“Complementary” is used herein in its usual way to indicate Watson-Crickbase pairing, and “non-complementary” is used to mean non-Watson-Crickbase pairing, even though such non-complementary sequences may formwobble pairs or other interactions. In the context of the presentinvention, reference to “non-pairing” sequences relates specifically tosequences between which Watson-Crick base pairs do not form.

The term “RNAi agent” refers to a dsRNA sequence that elicits RNAi. Thisterm may be used interchangeably with “small interfering RNAs” (siRNAagents) and small hairpin RNA (shRNAi or hpRNAi agents), wherein ahairpin has a stem-loop structure.

The “loop” of a hairpin structure is an additional sequence wherein atleast some of the nucleotides are non-complementary to either itself,the target sequence, the effector sequence or the effector complement.The loop can be a sequence of 2 to 100 nucleotides which are capable offorming a loop. Not all of the nucleotides of the loop sequence need benon-annealed. For example, in a loop sequence of ACUGUGAAGCAGAUGAGU,nucleotides ACU may be annealed with AGU, while the interveningGUGAAGCAGAUG sequence remains non-annealed.

In embodiments in which the ddRNAi agent is expressed as part of a miRNAstructure, the loop sequence may be derived from the miRNA, and isencoded by the ME sequence.

A “microRNA” or “miRNA” is a naturally occurring, small non-coding RNAmolecule present in organisms that functions in the post-transcriptionalregulation of gene expression. miRNA transcripts are capable of forminghairpin-like structures; typically contain mismatches and bulges withinor adjacent to the double stranded RNA regions. The miRNA structure inwhich the ddRNAi agents of the invention are preferably expressedcontains mismatches and insertions, as detailed above. Wu et al. (2011)showed that mismatched duplexes (containing mismatches in the passengerstrand) sometimes showed increased silencing activity, due possibly totheir greater structural resemblance to endogenous miRNAs. Similarly Guet al. (2012) showed the introduction of bulges adjacent to loopsequences in shRNA molecules can result in increased precision of Dicerprocessing.

In the double stranded, folded miRNA structure, at least 50% of thenucleotides on the top strand are annealed to nucleotides of the bottomstrand. Of the non-annealed (ie unpaired) nucleotides, they may beinsertions ie they lack a complementary nucleotide on the opposingstrand, or they may be mismatches such that they do not anneal. Forexample, a G and an A. The double stranded, folded miRNA structure cancontain 2 or more annealed nucleotides, separated by 1 or morenon-annealed nucleotides, to give a double stranded RNA structure with“bubbles” or ‘bulges” where the nucleotides are not annealed.

By “miRNA encoding sequence” or “ME sequence”, it is meant the DNAsequence contained within a ddRNAi expression cassette (see below fordefinition and description) that encodes for RNA which is capable offolding in to a miRNA structure. The effector sequence and the effectorcomplement of a ddRNAi agent is expressed within or as part of thatmiRNA structure. The ME sequence has a first and second part. In anexpression cassette for expressing a single hairpin (having one or moreeffector/effector complement pairs), the first part of the ME sequenceis located upstream (ie 5′) of the 5′ most effector or effectorcomplement encoding sequence, and the second part is located downstream(ie 3′) to the 3′ most effector or effector complement encodingsequence.

In the case of an expression cassette for a multiple hairpin structure,each effector/effector complement pair has a corresponding first andsecond ME sequence, wherein the first ME sequence is upstream of theeffector or effector complement encoding sequence and the second part isdownstream of the corresponding effector or effector complement encodingsequence. In an expression cassette having the following exemplarystructure, in a 5′ to 3′ direction:

-   -   a promoter    -   a first ME sequence;    -   a first effector;    -   a first effector complement sequence;    -   a second ME sequence;    -   a third ME sequence;    -   a second effector sequence;    -   a second effector complement sequence; and    -   a fourth ME sequence        it will be appreciated that the second and third ME sequence can        either be (using exemplary sequences to illustrate the point)        consecutive, can have intervening sequence between them, or can        be a single ME sequence that serves the same function as the        second and third ME sequence.

i) consecutive: ggtatattgctgttgacagtgagcgaggtatattgctggggacagtgaggccc        ME sequence 2          ME sequence 3 ii) intervening:ggtatattgctgttgacagtgagcgaATTGCCATGggtatattgctggggacagtgagccc        ME sequence 2       INTERVENING ME   sequence 3 iii) single:ggtatattgctgttgacagtgagcgaggtatattgctggggacagtgagccc            ME sequence

The double stranded or duplex region of the RNAi agent is at least 17base pairs long, and usually in the range of 17 to 30 base pairs. RNAiagents can be synthesized chemically or enzymatically outside of cellsand subsequently delivered to cells or can be expressed in vivo by anappropriate vector in cells (see, e.g., U.S. Pat. No. 6,573,099, WO2004/106517 and WO1999/49029, all of which are incorporated herein byreference).

The term “DNA-directed RNAi agent” or “ddRNAi agent” refers to an RNAiagent that is transcribed from a DNA expression cassette (“ddRNAiexpression cassette”). Depending on the arrangement of terminators andpromoters within the ddRNAi expression cassettes, they may expressddRNAi agents with single or multiple effector sequences, or may expressmultiple ddRNAi agents. A ddRNAi agent transcribed from the expressioncassette may be transcribed as a single RNA that is capable ofself-annealing into a single hairpin structure with a duplex regionlinked by at least 2 nucleotides. The single hairpin may include oneeffector sequence and its complement (see FIG. 1B or E) or multipleeffector sequences and their complements (see FIG. 1A or D).Alternatively, the agent may be a single RNA with multiple shRNA domains(ie multiple hairpin structures formed by the effector sequences andtheir complement—see FIG. 1C or F).

The ddRNAi expression cassette can be ligated into vectors referred toas ddRNAi vectors or ddRNAi constructs. The vectors may providesequences specifying transcription of the ddRNAi expression cassette invivo or in vitro. The vector may additionally serve as the deliveryvehicle for the ddRNAi expression cassette. Viral based vectors forexample will generate a ddRNAi construct that is useful for expressionof the ddRNAi expression cassette as well as being compatible with viraldelivery.

A cell has been “transformed”, “transduced” or “transfected” by anexogenous or heterologous nucleic acid or vector when such nucleic acidhas been introduced into the cell. The transforming DNA may or may notbe integrated (covalently linked) into the genome of the cell. Withrespect to eukaryotic cells, a stably transformed cell is one in whichthe transforming DNA has become integrated into a host cell chromosomeor is maintained extra-chromosomally (episomally) so that thetransforming DNA is inherited by daughter cells during cell replication.In non-replicating, differentiated cells the transforming DNA maypersist as an episome.

“Gene expression” can be a reference to either or both transcription ortranslation.

“Inhibition of expression” refers to the absence or observable decreasein the level of protein and/or mRNA product from the target gene. Theinhibition does not have to be absolute, but may be partial inhibitionsufficient for there to a detectable or observable change as a result ofthe administration of a RNAi or ddRNAi agent or siRNA agent or ddRNAiexpression cassette or expression construct of the invention. Inhibitionmay be measured by determining a decrease in the level of mRNA and/orprotein product from a target nucleic acid relative to a cell lackingthe ddRNAi agent or construct, and may be as little as 1%, 5% or 10%, ormay be absolute ie 100% inhibition. The effects of inhibition may bedetermined by examination of the outward properties ie quantitativeand/or qualitative phenotype of the cell or organism.

“Off-target” effects is a term used to describe unintentionalside-effects of treatment with an RNAi reagent. This is frequentlythought to involve unintended knockdown of a target sequence as aconsequence of chance homology with the passenger or effector sequencesand another target gene, although subtler effects arising from metaboliccompensation of a knockdown can also occur. Processing of miRNAs byendogenous RNAi pathways frequently results in the loading of only theeffector strand into RISC, and degradation of the passenger strand. Onepotential source of off-target effects is the unanticipatedincorporation of the passenger strand into RISC such that passengersequences can consequently silence genes which they fortuitously sharehomology with. There is evidence that a step in RISC loading “senses”the predicted thermodynamic stability of an RNA duplex across apotential target site in dsRNA precursors and preferentially loads thestrand whose 5′ end is from the less stable end of the duplex. Onestrategy to minimise the potential for off-target effects is to screenddRNAi molecules for activity of the passenger strand using DualLuciferase assays. Loading of this strand into RISC is undesirable.

As used herein, a “vascular endothelial growth factor-A gene” or “VEGF-Agene”, includes a gene that encodes a protein that stimulatesangiogenesis. In one embodiment the VEGF-A gene encodes a nucleotidesequence as shown in Genbank with accession number NM_001025366 (SEQ IDNO:79) which encodes human VEGF-A. In another embodiment, a VEGF-A geneis an orthologous or paralogous gene to the VEGF-A gene, including butnot limited to a nucleotide sequence as shown in Genbank with accessionnumber NM_001025250 (Mus musculus, SEQ ID NO:80) or XM_001089925 (Macacamulatta, SEQ ID NO:81). In another embodiment, the VEGF-A gene may be ahuman gene or gene from an animal as described herein and includesallelic variants.

As used herein, a “vascular endothelial growth factor receptor 2 gene”or “VEGFR2 gene” includes a gene that encodes a receptor for VEGF. Inone embodiment the VEGFR2 gene encodes a nucleotide sequence as shown inGenbank with accession number NM_002253 (SEQ ID NO: 82) which encodeshuman VEGFR2. In another embodiment, a VEGFR2 gene is an orthologous orparalogous gene to the VEGFR2, including but not limited to a nucleotidesequence as shown in Genbank with accession number NM_010612 (Musmusculus, SEQ ID NO:83) or XM_001086814 (Macaca mulatta, SEQ ID NO:84).In another embodiment, VEGFR2 gene may be a human gene or gene from ananimal as described herein and includes allelic variants.

As used herein, a “Beta-type platelet-derived growth factor receptorgene” or “PDGFR-β gene” includes a gene that encodes the PDGFR-βprotein. In one embodiment the PDGFR-β gene encodes a nucleotidesequence as shown in Genbank with accession number NM_002609 (SEQ IDNO:85) which encodes human PDGFR-β. In another embodiment, a PDGFR-βgene is an orthologous or paralogous gene to the PDGFR-β, including butnot limited to a nucleotide sequence as shown in Genbank with accessionnumber NM_001142706 (Mus musculus, SEQ ID NO:86) or XM_00110759 (Macacamulatta, SEQ ID NO:87). In another embodiment, PDGFR-β gene may be ahuman gene or gene from an animal as described herein and includesallelic variants.

As used herein, a “Complement Factor B gene” or “CFB gene” includes agene that encodes the CFB protein, a component of drusen. In oneembodiment the CFB gene encodes a nucleotide sequence as shown inGenbank with accession number NM_001710 (SEQ ID NO: 88) which encodeshuman CFB. In another embodiment, a CFB gene is an orthologous orparalogous gene to the CFB, including but not limited to a nucleotidesequence as shown in Genbank with accession number NM_00114270 (Musmusculus, SEQ ID NO:89) or XM_001113553 (Macaca mulatta, SEQ ID NO:90).

In another embodiment, CFB gene may be a human gene or gene from ananimal as described herein and includes allelic variants.

Sequences are “paralogous” if they are separated by a gene duplicationevent: if a gene in an organism is duplicated to occupy two differentpositions in the same genome, then the two copies are paralogous.

Sequences are “orthologous” if they are separated by a speciation event:when a species diverges into two separate species, the divergent copiesof a single gene in the resulting species are said to be orthologous.

As used herein, “a quantitative phenotypic trait” refers to a traitassociated with the molecular expression of a nucleic acid in a hostcell and may thus include the quantity of RNA molecules transcribed orreplicated, the quantity of post-transcriptionally modified RNAmolecules, the quantity of translated peptides or proteins, or theactivity of such peptides or proteins.

A reduction of phenotypic expression of a nucleic acid where thephenotype is a qualitative trait means that in the presence of the RNAiagent of the invention, the phenotypic trait switches to a differentstate when compared to a situation in which the RNAi agent is absent. Areduction of phenotypic expression of a nucleic acid may thus bemeasured as a reduction in steady state levels of (part of) that nucleicacid, a reduction in translation of (part of) that nucleic acid or areduction in the effect the presence of the transcribed RNA(s) ortranslated polypeptide(s) have on the eukaryotic cell or the organism,and will ultimately lead to altered phenotypic traits. It is clear thatthe reduction in phenotypic expression of a nucleic acid of interest maybe accompanied by or correlated to an observable change in phenotype.The assessment may be by way of biochemical techniques such as Northernhybridisation, quantitative real-time PCR assays, gene expressionassays, antibody binding, ELISA, RIA, western blotting and other assaysand techniques known in the art.

“Target nucleic acids” may be either RNA or DNA, whose transcriptionproducts are targeted, coding or non-coding sequence, endogenous orexogenous.

A “therapeutic composition” or “pharmaceutical composition” or“composition for treating” refers to a composition including a ddRNAiagent, ddRNAi expression cassette, ddRNAi construct or siRNA agent.

The words “treat” or “treatment” refer to therapeutic treatment whereinthe object is to slow down (lessen) an undesired physiological change ordisorder. For purposes of this invention, beneficial or desired clinicalresults include, but are not limited to, alleviation of symptoms of AMD,stabilised (i.e., not worsening or progressing) AMD, and stabilised CNV.

The phrase “therapeutically effective amount” means an amount of acompound of the present invention that (i) treats the particulardisease, condition, or disorder, (ii) attenuates, ameliorates, oreliminates one or more symptoms of the particular disease, condition, ordisorder, (iii) prevents or delays the onset of one or more symptoms ofthe particular disease, condition, or disorder described herein, (iv)prevents or delays progression of the particular disease, condition ordisorder, or (v) reverses damage caused prior to treatment to someextent. The reversal does not have to absolute, but any clinicallyrelevant return of visual acuity post-treatment is considered a reversalof damage.

The current invention provides a new RNAi agent, and use of the RNAiagent for reducing the regression of visual acuity associated with AMDin affected individuals, particularly those with wet AMD. Treatment isaimed at one or more of:

i. controlling angiogensis associated with choroidal neovascularisation(CNV) by long-term knock down of VEGF-A translation and subsequentsecretion from retina cells using a DNA construct containing one or moresequences aimed at silencing specific genes associated with VEGF-Aexpression. VEGF-A stimulates angiogenesis, and therefore the abnormaloutgrowth of blood vessels from the vasculature behind the retina. Anumber of existing therapies only serve to “mop up” secreted VEGF-A,which may stabilise vision, but does not necessarily improve vision inall patients.ii. Additional control of angiogenesis might be obtained by knockdown ofboth VEGF-A and its receptor VEGFR2, since this strategy would beexpected to interfere with the process at two distinct steps.iii. Reversal of AMD might be achieved by knockdown of three targets,namely VEGFR2, PDGFR-β and CFB. VEGFR2 knockdown would be expected tocontrol angiogenesis, PDGFR-β knockdown would be expected to inhibit orreverse nascent blood vessel formation and CFB knockdown would beexpected to inhibit or even reverse drusen depositioniv) limiting treatment frequency, and limiting treatment to RPE cellsvia localised injection of the therapeutic molecules.

Identifying appropriate target sequences within target genes, anddesigning RNAi agents that work based on those sequences, is notroutine. As will be demonstrated in the results section, targetsequences that look like good candidates on paper, may not necessarilyeffectively silence the target, or may not do so to an effective levelfor therapeutic purposes. Some effector sequences work much moreeffectively than others to silence a target in particular incorporationof passenger strands into RISC is undesirable since this may lead tosignificant off-target effects and consequent toxicity. But it is notpredictable which sequences are able to be silenced by mere visualinspection of the sequence itself, let alone to what extent they may besilenced, and if that would be sufficient for the purposes of theinvention. Even more so when you are seeking to silence 2 or moreunrelated targets.

Despite the recognition in the art that VEGF-A is a suitable target forAMD therapies, efforts to create an effective therapy to date have beenplagued by the problems summarised in the background. With respect tosilencing by RNAi techniques in particular, previous efforts using invitro produced siRNA agents have been unsuccessful due to siRNAinteraction with membrane bound TLR3 and subsequent activation ofinterferon. In addition, cells which secrete the majority of VEGF-A arethe RPE cells, generally found buried underneath layers of specializedcells towards the back of the eye. RNAi moieties are highly chargedcomplexes and can be difficult to traverse across multiple layers ofcells because of this physical property. The new range of targets, theddRNAi agents and the viral delivery agents utilised seek to overcomethese issues.

In addition to VEGF-A these targets include one or more of:

-   -   VEGFR2: the receptor for VEGF-A; silencing VEGFR2 is expected to        have similar consequences to silencing VEGF-A    -   PDGFR-β: the receptor for PDGFR-β. This molecule plays a role in        recruitment and stabilisation of endothelial cells, which is        critical for stabilisation of nascent blood vessels.    -   CFB: This is a major component of drusen, the hallmark        extracellular deposit associated with AMD. (Anderson et al        2010). Silencing CFB may inhibit the formation of drusen.

RNA interference (RNAi) is an RNA-dependent gene silencing process thatis initiated by short double-stranded RNA molecules in a cell'scytoplasm. In mammals, RNAi is mediated by double-stranded RNA moleculesreferred to as small interfering RNAs (siRNA). The double stranded, orduplex region of the RNAi agent is at least 17 base pairs long, andusually in the range of 17 to 30 base pairs. RNAi agents can besynthesised chemically or enzymatically outside of cells andsubsequently delivered to cells or can be expressed in vivo by anappropriate vector in cells (such as AAV, adenovirus, lentivirus, ornon-viral liposome-based delivery systems).

Pre-clinical testing of RNAi agents as AMD therapeutics requires theextensive use of animal models. Mouse (Mus muscularis) and primate (egmacaques, Macaca fasciularis) models are widely used to test theefficacy of treatments, and other species such as dogs (Canisfamiliaris) are commonly used as models to determine the clinical safetyof therapeutic compounds. For RNAi therapeutics it is advantageous todesign reagents that target nucleotide sequences of AMD-associated genesthat are highly conserved between humans and the various pre-clinicaltest species since a single RNAi reagent can be used at all stages ofpre-clinical testing. For poorly conserved genes multiple RNAi reagentswith sequences that differ slightly between the different test speciesmust be tested in parallel to accurately determine potential toxicity.

Accordingly, the RNAi reagents described in this application are, wherepossible, designed to target sequences conserved between humans and thepotential test species (mice, dogs and primates such as macaques), sincethis provides significant advantages for a drug development program.

ddRNAi Agent

RNAi agents may be expressed from DNA vectors, referred to asDNA-directed RNAi, or ddRNAi. They can directly target the activity ofgenes with minimum off-target events. In the case of AMD, this offers aunique opportunity to address the unmet clinical treatment needs.Accordingly, in one aspect of the invention, there is provided aDNA-directed RNA interference (ddRNAi) agent for inhibiting expressionof one or more target sequences in an AMD-associated gene, the ddRNAiagent comprising at least:

-   -   a first effector sequence of at least 17 nucleotides in length;        and    -   a first effector complement sequence;        wherein the first effector sequence is complementary or        substantially complementary to one or more target regions in a        transcript of the one or more target sequences.

Typically, the first effector sequence forms a double stranded regionwith the first effector complement sequence.

The sequences of the ddRNAi agents of the invention have to have asufficient identity to the AMD-associated gene, such as the VEGF-A,VEGFR2, CFB and PDGFR-β genes, in order to mediate target specific RNAi.

The first effector sequence is at least 17 nucleotides long, preferably17 to 30 nucleotides and more preferably 17 to 21 nucleotides. It may be17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides inlength. When the first effector sequence is longer than 17 nucleotides,it is preferred that at least 17 contiguous nucleotides of the firsteffector sequence forms the double stranded region with thecomplementary strand. A ddRNAi agent according to this embodiment of theinvention therefore has a maximum length determined by the length andnumber of effector sequence/s ie each effector sequence is not comprisedwithin a longer sequence.

The ddRNAi agents of the invention inhibit expression of AMD-associatedtarget genes. Preferably the AMD-associated gene is VEGF-A, or one ormore of VEGFR2, CFB and PDGFR-β, and each effector sequence is selectedfrom the group consisting of any 10 or more contiguous nucleotideswithin a sequence from any one of SEQ ID NOS: 40-78.

As illustrated in the table below, when the AMD-associated gene to beinhibited, prevented or reduced is VEGF-A, each effector sequence isselected from SEQ ID NOS: 40-49. When the AMD-associated gene to beinhibited, prevented or reduced is VEGFR2 each effector sequence isselected from SEQ ID NOS: 50-59. When the AMD-associated gene to beinhibited, prevented or reduced is PDGFR-β, each effector sequence isselected from SEQ ID NOS: 60-69. When the AMD-associated gene to beinhibited, prevented or reduced is CFB, each effector sequence isselected from SEQ ID NOS: 70-78.

TABLE 1 VEGF-A, VEGFR2, CFB and PDGFR-β gene target sequences and theircorresponding ddRNAi effector sequences Target SEQ Target sequence in 5′SEQ Corresponding effector Target^(a) position^(b) ID NO to 3′direction^(c) ID NO sequence in 5′ to 3′ direction^(d) VEGF-A  328-348 1 AGCAAGAGCTCCAGAGAGAAG 40 CUUCUCUCUGGAGCUCUUGCU miR-1 VEGF-A 1026-1046 2 GGCCTCCGAAACCATGAACTT 41 AAGUUCAUGGUUUCGGAGGCC miR-2 VEGF-A 1203-1223 3 CGAGACCCTGGTGGACATCTT 42 AAGAUGUCCACCAGGGUCUCG miR-3 VEGF-A 1383-1403 4 GCACATAGGAGAGATGAGCTT 43 AAGCUCAUCUCUCCUAUGUGC miR-4 VEGF-A 1422-1442 5 TGAATGCAGACCAAAGAAAGA 44 UCUUUCUUUGGUCUGCAUUCA miR-5 VEGF-A 1858-1878 6 CAGAACAGTCCTTAATCCAGA 45 UCUGGAUUAAGGACUGUUCUG miR-6 VEGF-A 2055-2075 7 TCTGGGATTCCTGTAGACACA 46 UGUGUCUACAGGAAUCCCAGA miR-7 VEGF-A 2067-2087 8 GTAGACACACCCACCCACATA 47 UAUGUGGGUGGGUGUGUCUAC miR-8 VEGF-A 3480-3500 9 GGTGCTACTGTTTATCCGTAA 48 UUACGGAUAAACAGUAGCACC miR-9 VEGF-A 3554-357410 CGAGATATTCCGTAGTACATA 49 UAUGUACUACGGAAUAUCUCG miR-10 VEGFR2  477-49711 TTGGACTGGCTTTGGCCCAAT 50 AUUGGGCCAAAGCCAGUCCAA miR-V-1 VEGFR2 864-884 12 CCCAGCTACATGATCAGCTAT 51 AUAGCUGAUCAUGUAGCUGGG miR-V-2VEGFR2 2625-2645 13 GCCATGTTCTTCTGGCTACTT 52 AAGUAGCCAGAAGAACAUGGCmiR-V-3 VEGFR2 2661-2681 14 CGGACCGTTAAGCGGGCCAAT 53AUUGGCCCGCUUAACGGUCCG miR-V-4 VEGFR2 3037-3057 15 TCATGGTGATTGTGGAATTCT54 AGAAUUCCACAAUCACCAUGA miR-V-5 VEGFR2 3299-3319 16CCTGACCTTGGAGCATCTCAT 55 AUGAGAUGCUCCAAGGUCAGG miR-V-6 VEGFR2 3307-332717 TGGAGCATCTCATCTGTTACA 56 UGUAACAGAUGAGAUGCUCCA miR-V-7 VEGFR23338-3358 18 GGCTAAGGGCATGGAGTTCTT 57 AAGAACUCCAUGCCCUUAGCC miR-V-8VEGFR2 3698-3718 19 ACCAGAAATGTACCAGACCAT 58 AUGGUCUGGUACAUUUCUGGTmiR-V-9 VEGFR2 3928-3948 20 ACCCCAAATTCCATTATGACA 59UGUCAUAAUGGAAUUUGGGGT miR-V-10 PDGFR-β 1093-1113 21ACTCCAGGTGTCATCCATCAA 60 UUGAUGGAUGACACCUGGAGU miR-P-1 PDGFR-β 1098-111822 AGGTGTCATCCATCAACGTCT 61 AGACGUUGAUGGAUGACACCU miR-P-2 PDGFR-β2197-2217 23 CCATGAGTACATCTACGTGGA 62 UCCACGUAGAUGUACUCAUGG miR-P-3PDGFR-β 2872-2892 24 GGACCTCGTGGGCTTCAGCTA 63 UAGCUGAAGCCCACGAGGUCCmiR-P-4 PDGFR-β 2977-2997 25 AGGCAAGCTGGTCAAGATCTG 64CAGAUCUUGACCAGCUUGCCU miR-P-5 PDGFR-β 3085-3105 26 GGAGAGCATCTTCAACAGCCT65 AGGCUGUUGAAGAUGCUCUCC miR-P-6 PDGFR-β 3090-3110 27GCATCTTCAACAGCCTCTACA 66 UGUAGAGGCUGUUGAAGAUGC miR-P-7 PDGFR-β 3181-320228 CCCAGAGCTGCCCATGAACGA 67 UCGUUCAUGGGCAGCUCUGGG miR-P-8 PDGFR-β3202-3222 29 GCAGTTCTACAATGCCATCAA 68 UUGAUGGCAUUGUAGAACUGC miR-P-9PDGFR-β 3250-3270 30 CCATGCCTCCGACGAGATCTA 69 UAGAUCUCGUCGGAGGCAUGGmiR-P-10 CFB  929-949 31 CTGCCAAGACTCCTTCATGTA 70 UACAUGAAGGAGUCUUGGCAGmiR-C-1 CFB 1085-1105 32 GAACATCTACCTGGTGCTAGA 71 UCUAGCACCAGGUAGAUGUUCmiR-C-2 CFB 1096-1116 33 TGGTGCTAGATGGATCAGACA 72 UGUCUGAUCCAUCUAGCACCAmiR-C-3 CFB 1100-1120 34 GCTAGATGGATCAGACAGCAT 73 AUGCUGUCUGAUCCAUCUAGCmiR-C-4 CFB 1535-555 35 GGAGGATTATCTGGATGTCTA 74 UAGACAUCCAGAUAAUCCUCCmiR-C-5 CFB 1697-1717 36 GTCTCTGAGTCTCTGTGGCAT 75 AUGCCACAGAGACUCAGAGACmiR-C-6 CFB 1817-1837 37 GGCTGTGGTGTCTGAGTACTT 76 AAGUACUCAGACACCACAGCCmiR-C-7 CFB 2154-2174 38 CAGGATATCAAAGCTCTGTTT 77 AAACAGAGCUUUGAUAUCCUGmiR-C-8 CFB 2201-2221 39 TCGGAAGGAGGTCTACATCAA 78 UUGAUGUAGACCUCCUUCCGAmiR-C-9 ^(a)Target genes are human VEGF-A (NM_0010253660), VEGFR2(NM_002253), PDGFR-β (NM_002609) and CFB (NM_001710); designations belowgene names refer to versions of ddRNAi constructs targeting theparticular genes. ^(b)Target positions for human sequences listed.^(c)Target sequences are the DNA sequences recognised by the effectorsequence. ^(d)Effector sequences are the predicted RNA sequencesproduced by dicer processing of the ddRNAi agents that targetAMD-associated genes; T refers to constructs where effector is modifiedto maintain structure of the expressed RNAs.

The ddRNAi agents of the invention are preferably expressed within or aspart of a miRNA structure. These miRNA structures have the sequencesshown as “miR sequences” and are listed in Table 2 (SEQ ID NOS: 91-129),which were designed to express the indicated effector sequences (SEQ IDNOS: 40-78). The corresponding constructs containing the expressioncassettes for expressing the miRNA structures is also shown as“miR-designations”.

TABLE 2 miR constructs displaying strong, sequence- specific silencingof AMD-associated genes SEQ ID NO: SEQ ID NO: AMD Target miRdesignations^(a) miR sequence^(b) effector sequence^(c) VEGF-A miR-1 9140 miR-2 92 41 miR-3 93 42 miR-4 94 43 miR-5 95 44 miR-6 96 45 miR-7 9746 miR-8 98 47 miR-9 99 48 miR-10 100 49 VEGFR2 miR-V-1 101 50 miR-V-2102 51 miR-V-3 103 52 miR-V-4 104 53 miR-V-5 105 54 miR-V-6 106 55miR-V-7 107 56 miR-V-8 108 57 miR-V-9 109 58 miR-V-10 110 59 PDGFR- βmiR-P-1 111 60 miR-P-2 112 61 miR-P-3 113 62 miR-P-4 114 63 miR-P-5 11564 miR-P-6 116 65 miR-P-7 117 66 miR-P-8 118 67 miR-P-9 119 68 miR-P-10120 69 CFB miR-C-1 121 70 miR-C-2 122 71 miR-C-3 123 72 miR-C-4 124 73miR-C-5 125 74 miR-C-6 126 75 miR-C-7 127 76 miR-C-8 128 77 miR-C-9 12978 ^(a)miR constructs tested for silencing activity and favourablestrand specificities against the indicated human target genes (see FIGS.4-7). ^(b)SEQ ID NOS corresponding to inserts of miR constructs. ^(c)SEQID NOS of predicted effector sequences produced by indicated miRconstructs.

Any of the ddRNAi agents of the invention can be expressed within or aspart of a miRNA structure. As will be explained throughout thespecification, this can assist with more accurate processing of theddRNAi agent, and lower toxicity within the cell.

In one embodiment of the invention, the ddRNAi agent of the inventioninhibits expression of one or more target sequences in a VEGF-A gene. Atarget sequence is preferably selected from the ddRNAi VEGF-A targetsequences listed in Table 1 (SEQ ID NOS: 1-10); the correspondingeffector sequences that would be produced by dicer processing of addRNAi agent targeting those sequences is shown in SEQ ID NOS: 40-49respectively. Note that the VEGF-A target sequences and effectorsequences have been chosen to show conservation of nucleotide sequencesbetween human and the pre-clinical test species mouse, dog and macaque.

In an alternative embodiment of the invention, the ddRNAi agent of theinvention inhibits expression of one or more target sequences in aVEGFR2 gene. A target sequence is preferably selected from the ddRNAi aVEGFR2 target sequences listed in Table 2 (SEQ ID NOS: 11-20); thecorresponding effector sequences are therefore selected from SEQ ID NOS:50-59 respectively as shown in Table 2. Note that the VEGFR2 target (SEQID NOS: 11-20) and effector sequences (SEQ ID NOS: 50-59) are identicalto, or differ by only a single nucleotide between human and thepre-clinical test species mouse and macaque.

In an alternative embodiment of the invention, the ddRNAi agent of theinvention inhibits expression of one or more target sequences in aPDGFR-β gene. A target sequence is preferably selected from the ddRNAiPDGFR-β target sequences listed in Table 2 (SEQ ID NOS: 21-30); thecorresponding effector sequences are therefore selected from SEQ ID NOS:60-69 respectively as shown in Table 2. Note that the PDGFR-β target(SEQ ID NOS: 21-30) and effector sequences (SEQ ID NOS: 60-69) areidentical to, or differ by only a single nucleotide between human andthe pre-clinical test species mouse and macaque.

In an alternative embodiment of the invention, the ddRNAi agent of theinvention inhibits expression of one or more target sequences in a CFBgene. A target sequence is preferably selected from the ddRNAi CFBtarget sequences listed in Table 1 (SEQ ID NOS: 31-39); thecorresponding effector sequences are therefore selected from SEQ ID NOS:70-78 respectively as shown in Table 2. Note that the CFB target (SEQ IDNOS: 31-39) and effector sequences (SEQ ID NOS: 70-78) are identical to,or differ by only a single nucleotide between human and the pre-clinicaltest species mouse and macaque.

In accordance with the explanation provided earlier, the relationshipbetween the DNA target sequence and the corresponding effector sequenceof the ddRNAi agent can be shown as (using the target SEQ ID NO:2 andits corresponding effector sequence SEQ ID NO:41 from Table 1):

-   -   5′ GGCCTCCGAAACCATGAACTT 3′—target sequence of VEGF-A (SEQ ID        NO:2)    -   5′ GGCCUCCGAAACCAUGAACUU 3′—mRNA transcript of SEQ ID NO:2    -   3′ AAGUUCAUGGUUUCGGAGGCC 5′—effector sequence of ddRNAi agent        (SEQ ID NO:41) to target SEQ ID NO:2, which when read in the 5′        to 3′ direction, can be seen to be substantially complementary        to the transcript of the target sequence.

As explained in the background section, both strands of the ddRNAi agenthave the potential to be the effector sequence. However there isevidence that particular features of a sequence can favour one strand toenter the RISC and the other strand to be destroyed. There is evidencethat a step in RISC loading “senses” thermodynamic stability of an RNAduplex across a potential target site in dsRNA precursors andpreferentially loads the strand whose 5′ end is from the less stable endof the duplex. Therefore target site sequences were typically adjustedto maximise the number of AT base pairs at the 3′ end of the targetsite, i.e. maximising the number of A or U bases in the 5′ end of theeffector strand. The list of refined target sites was then screened forconservation between likely test species, specifically mice and monkeys.Target site sequences were then screened against the humantranscriptome, using BLAST, and those showing high homology to otherhuman genes (>3 mismatches) were discarded. Constructs based on thesetarget sequences were prepared in a miRNA backbone and testedempirically for activity and strand selectivity as described below.These sequence preferences are reflected in preferred embodiments, anddata is provided in the examples section showing the advantages of somesequences over other.

For example, in one embodiment of this aspect of the invention, there isprovided a DNA-directed RNA interference (ddRNAi) agent for inhibitingexpression of one or more target sequences in an AMD-associated gene,the ddRNAi agent comprising at least:

-   -   a first effector sequence of any 10 or more contiguous        nucleotides within 5′ UAUGUGGGUGGGUGUGUCUAC 3′ (SEQ ID NO:47);        and    -   a first effector complement sequence.

The first effector sequence is substantially complementary to a targetregion in a transcript of one or more target sequences in anAMD-associated gene. In this example, the target gene is VEGF-A.

Preferably the first effector sequence is at least 17 or more contiguousnucleotides within 5′ UAUGUGGGUGGGUGUGUCUAC 3′ (SEQ ID NO:47).

When the first effector sequence has 1, 2, 3, 4 or 5 nucleotidesdifferent to SEQ ID NO:47, the differences are preferably present in thefirst and/or last 5 nucleotides, and preferably at least the centre 10nucleotides are 100% complementary to a target region in a transcript ofone or more target sequences.

In alternative embodiments, the ddRNAi agent comprises a first effectorsequence of any 10 or more, preferably any 17 or more, contiguousnucleotides within SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ IDNO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ IDNO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ IDNO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ IDNO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62, SEQ IDNO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ IDNO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ IDNO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77 or SEQ IDNO:78.

In particularly preferred embodiments, the ddRNAi agent comprises afirst effector sequence of any 10 or more, preferably any 17 or more,contiguous nucleotides within sequences able to inhibit the expressionof a target gene region by at least 70%. Preferably, in this embodiment,the first effector is selected from SEQ ID NO:47, which targets asequence of SEQ ID NO:8.

The first effector sequence may comprise a sequence selected from any 10or more and preferably any 17 or more contiguous nucleotides within asequence from the group consisting of SEQ ID NOS: 40-78, oralternatively, each effector sequence may be a variant of SEQ IDNOS:40-78, having 1, 2, 3, 4 or 5 nucleotide variations. In yet afurther embodiment, each effector sequence may consist of 20nucleotides, of which 17, 18, 19, or all 20 nucleotides are contiguousnucleotides from a sequence selected from the group consisting of SEQ IDNOS: 40-78.

Multiple Targeting ddRNAi Agents

ddRNAi agents with multiple effector sequences have the advantage ofbeing able to target a range of molecular targets and naturallyoccurring variants thereof that may exist between individuals, as wellas the advantage of the additive or synergistic effects achieved withmultiple effector sequences as opposed to single effector sequences. Inthe present invention, where in one embodiment there are 2 or 3different target genes selected from VEGF-A, VEGFR2, CFB and PDGFR-β, itis particularly advantageous for a single construct to be utilised totarget the 2 or 3 genes. This eliminates the need to deliver multipleddRNAi agents each targeting a different gene. As would be appreciatedby the person skilled in the art, it would be difficult to ensure thatdelivery would result in equal and sufficient concentrations of each ofthe agents.

In one embodiment of the invention, the ddRNAi agent comprises two ormore effector sequences to enable targeting of more than one targetsequence of the AMD-associated gene. The multiple target sequences maybe in the same region of the one gene. For example, a 17 to 30nucleotide region, preferably a 17 to 21 nucleotide region, withinVEGF-A, VEGFR2, CFB or PDGFR-β that has natural variation in thesequence between individuals. Alternatively, the target sequences may bein different regions of the one target gene, where the target gene maybe VEGF-A, VEGFR2, CFB or PDGFR-β.

As noted above the target sequences may also be in differentAMD-associated genes. For example, a first effector sequence targets asequence in VEGFR2, whereas a second effector sequence in the sameddRNAi agent targets a sequence in a VEGF-A gene. In a preferredembodiment, there are at least 2 effector sequences, each one targetinga sequence in each of VEGF-A and VEGFR. In an alternative embodiment,there are at least 3 effector sequences, each one targeting a sequencein each of VEGFR2, CFB and PDGFR-β.

To provide greater specificity the ddRNAi agent comprises the following(in no particular order):

-   -   a first effector sequence of at least 17 nucleotides in length;    -   a second effector sequence of at least 17 nucleotides in length;    -   a first effector complement sequence; and    -   a second effector complement sequence.

The first and second effector sequences of a multiple targeting ddRNAiagent form a double stranded region with their respective effectorcomplements. Preferably, the first and second effector sequences are 17to 30 nucleotides in length. More preferably, the first and secondeffector sequence are both selected from any 10 or more and preferablyany 17 or more contiguous nucleotides within any one of the sequences ofSEQ ID NOS: 40-78 listed in Table 1 above, or are sequences having 1, 2,3, 4 or 5 nucleotides difference from those sequences listed in Table 1.

In one embodiment, the first effector sequence is selected from any 10or more and preferably any 17 or more contiguous nucleotides within asequence from any one of the group consisting of SEQ ID NOS:40-78, andthe second effector sequence is selected from any 10 or more andpreferably any 17 or more contiguous nucleotides within a sequence fromany one of the group consisting of SEQ ID NOS: 40-78. The first andsecond effector sequence may both be the same sequence or mayalternatively be different sequences.

The first and second effector sequence may each comprise a sequenceselected from any 10 or more contiguous nucleotides within a sequencefrom the group consisting of SEQ ID NOS: 40-78, or alternatively, eacheffector sequence may also be a variant of SEQ ID NOS: 40-78, having 1,2, 3, 4 or 5 nucleotide variations. In yet a further embodiment, eacheffector sequence may consist of 20 nucleotides, of which 17, 18, 19, orall 20 nucleotides are contiguous nucleotides from a sequence selectedfrom the group consisting of SEQ ID NOS: 40-78. When there are two ormore effector sequences, they may represent a combination of the 3 typesdescribed above.

In particularly preferred embodiments, the first and second effectorsequence comprise any 10 or more, preferably any 17 or more, contiguousnucleotides within sequences able to inhibit the expression of a targetgene region by at least 70%. Preferably in this embodiment, eacheffector sequence is selected from any 10 or more and preferably any 17or more contiguous nucleotides within a sequence consisting of SEQ IDNO:47 and SEQ ID NO:56 such that there is provided a DNA-directed RNAinterference (ddRNAi) agent for inhibiting expression of one or moretarget sequences in an AMD associated gene, the ddRNAi agent comprising,in a 5′ to 3′ direction

-   -   a first effector sequence of any 10 or more contiguous        nucleotides within 5′ UAUGUGGGUGGGUGUGUCUAC 3′ (SEQ ID NO:47);    -   a first effector complement sequence;    -   a second effector sequence of any 10 or more contiguous        nucleotides within 5′ UGUAACAGAUGAGAUGCUCCA 3′ (SEQ ID NO:56);        and    -   a second effector complement sequence        wherein each effector sequence is substantially complementary        one or more target regions in a transcript of the one or more        target sequences.

Long Hairpin Version

When the ddRNAi agent contains more than one effector sequence, and theddRNAi agent is expressed as a single strand of RNA, it will fold toform different structures depending on the order of the effectorsequences and the sequences complementary to the effector sequences. Inone embodiment, there is provided a DNA-directed RNA interference(ddRNAi) agent for inhibiting expression of one or more target sequencesin an AMD-associated gene, preferably a VEGF-A gene and/or one or moreof a VEGFR2, CFB and PDGFR-β gene, the ddRNAi agent comprising, in a 5′to 3′ direction, at least:

-   -   a first effector sequence of at least 17 nucleotides in length;    -   a second effector sequence of at least 17 nucleotides in length;    -   a second effector complement sequence; and    -   a first effector complement sequence        wherein each effector sequence is substantially complementary to        one or more target regions in a transcript of the one or more        target sequences. This will result in a ddRNAi agent with a        structure as shown in FIG. 1A. See also WO2004/106517,        incorporated herein by reference.

Alternatively, at least one effector, and preferably both effectorsequences, are 100% complementary one or more target regions in atranscript of the one or more target sequences. Preferably the first andsecond effector sequences are both selected from the group consisting ofany 10 or more and preferably any 17 or more contiguous nucleotideswithin any one of SEQ ID NOS: 40-78. For example, in one embodiment,there is provided a DNA-directed RNA interference (ddRNAi) agent forinhibiting expression of one or more target sequences in anAMD-associated gene, the ddRNAi agent comprising, in a 5′ to 3′direction, at least:

a first effector sequence of (SEQ ID NO: 41) 5′AAGUUCAUGGUUUCGGAGGCC 3′, a second effector sequence (SEQ ID NO: 44) 5′UCUUUCUUUGGUCUGCAUUCA 3′,

-   -   a second effector complement; and    -   a first effector complement        wherein the AMD-associated gene is VEGF-A.

Each effector sequence is substantially complementary to one or moretarget regions in a transcript of the one or more target sequences.

Alternatively, at least one effector, and preferably both effectorsequences, are 100% complementary to one or more target regions in atranscript of the one or more target sequences.

In particularly preferred embodiments, the first and second effectorsequence comprise any 10 or more, preferably any 17 or more, contiguousnucleotides within sequences able to inhibit the expression of a targetgene region by at least 70%. Preferably, in this embodiment, eacheffector sequence is selected from SEQ ID NOS: 40-78, more preferablyfrom SEQ ID NOS: 40-59 and most preferably SEQ ID NOS: 40-49.

In yet another embodiment, being an embodiment where the ddRNAi agenthas 3 effector sequences, there is provided a DNA-directed RNAinterference (ddRNAi) agent for inhibiting expression of one or moretarget sequences in the target gene, the ddRNAi agent comprising, in a5′ to 3′ direction, at least:

a first effector sequence of (SEQ ID NO: 41) 5′AAGUUCAUGGUUUCGGAGGCC 3′, a second effector sequence of (SEQ ID NO: 44)5′ UCUUUCUUUGGUCUGCAUUCA 3′, a third effector sequence of(SEQ ID NO: 47) 5′ UAUGUGGGUGGGUGUGUCUAC 3′,

-   -   a third effector complement sequence;    -   a second effector complement sequence; and    -   a first effector complement sequence.

Each effector sequence is substantially complementary to one or moretarget regions in a transcript of the one or more target sequences.

Alternatively, at least one effector, and optionally 2 out of the 3 orall 3 of the effectors, are 100% complementary to one or more targetregions in a transcript of the one or more target sequences.

In particularly preferred embodiments, the first, second and thirdeffector sequence comprise any 10 or more, preferably any 17 or more,contiguous nucleotides within sequences able to inhibit the expressionof a target gene region by at least 70%.

Preferably, in this embodiment, each effector sequence is selected fromSEQ ID NOS:40-78, more preferably from SEQ ID NOS: 40-59, and mostpreferably from SEQ ID NOS: 40-49.

It will also be appreciated by the skilled person that the order ofeffector and effector complements can be altered, provided that asingle, long hairpin structure is formed by annealing of the effectorsequence with its effector complement to form dsRNA. For example, in a2-effector sequence ddRNAi agent, the sequences may be arranged in thefollowing exemplary 5′ to 3′ orders:

-   -   first effector-second effector-second effector complement-first        effector complement;    -   second effector-first effector-first effector complement-second        effector complement;    -   first effector-second effector complement-second effector-first        effector complement;    -   first effector complement-second effector complement-second        effector-first effector;    -   first effector complement-second effector-second effector        complement-first effector.

In a 3-effector sequence ddRNAi agent, the sequences may be arranged inthe following exemplary 5′ to 3′ orders:

-   -   first effector-second effector-third effector-third effector        complement-second effector complement-first effector complement    -   first effector-second effector complement-third effector-third        effector complement-second effector-first effector complement;    -   first effector-second effector-third effector complement-third        effector-second effector complement-first effector complement    -   first effector-third effector-second effector complement-second        effector-third effector complement-first effector complement    -   first effector complement-second effector complement-third        effector complement-third effector-second effector-first        effector complement    -   first effector complement-second effector complement-third        effector-third effector complement-second effector-first        effector.

In yet further embodiments, the first effector sequence may be selectedfrom any 10 or more and preferably any 17 or more contiguous nucleotideswithin a sequence from the group consisting of SEQ ID NOS:40-78; thesecond effector sequence may be selected from any 10 or more andpreferably any 17 or more contiguous nucleotides within a sequence fromthe group consisting of SEQ ID NOS:40-78; the third effector sequencemay be selected from any 10 or more and preferably any 17 or morecontiguous nucleotides within a sequence from the group consisting ofSEQ ID NOS:40-78; and any further effector sequences may be selectedfrom any 10 or more and preferably any 17 or more contiguous nucleotideswithin a sequence from the group consisting of SEQ ID NOS:40-78.Alternatively, each effector sequence may also be a variant of SEQ IDNOS:40-78, having 1, 2, 3, 4 or 5 nucleotide variations. Preferably, thedifferences are present in the first and/or last 5 nucleotides, and atleast the centre 11-12 nucleotides are 100% complementary to one or moretarget regions in a transcript of the one or more target sequences. Ineach of the embodiments, wherein only VEGF-A is to be targeted, eacheffector sequence is selected from SEQ ID NOS: 40-49; wherein onlyVEGFR2 is to be targeted, each effector sequence is selected from SEQ IDNOS: 50-59; wherein only PDGFR-β is to be targeted, each effectorsequence is selected from SEQ ID NOS: 60-69; and wherein only CFB is tobe targeted, each effector sequence is selected from SEQ ID NOS: 70-78.

The first, second and third effector sequence may each comprise asequence selected from any 10 or more contiguous nucleotides within asequence from the group consisting of SEQ ID NOS: 40-78, oralternatively, each effector sequence may also be a variant of SEQ IDNOS:40-78, having 1, 2, 3, 4 or 5 nucleotide variations. In yet afurther embodiment, each effector sequence may consist of 20nucleotides, of which 17, 18, 19, or all 20 nucleotides are contiguousnucleotides from a sequence selected from the group consisting of SEQ IDNOS: 40-78. When there are multiple effector sequences, they mayrepresent a combination of the 3 types described above.

Multiple Hairpin Version

In an alternative embodiment, there is provided a DNA-directed RNAinterference (ddRNAi) agent for inhibiting expression of one or moretarget sequences in one or more AMD-associated genes, preferably aVEGF-A, VEGFR2, CFB or PDGFR-β genes, the ddRNAi agent comprising, in a5′ to 3′ direction, at least:

-   -   a first effector sequence of at least 17 nucleotides in length;    -   a first effector complement;    -   a second effector sequence of at least 17 nucleotides in length;        and    -   a second effector complement        wherein each effector sequence is substantially complementary to        one or more target regions in a transcript of the one or more        target sequences.

Alternatively, at least one effector, and preferably both effectorsequences, is 100% complementary to the one or more target regions of atranscript of the one or more target sequences.

This will result in a ddRNAi agent with a structure as shown in FIG. 1Bor C, depending on the type of expression cassette used to express it(see later in the specification). See also WO2005/087926 andWO2006/084209, incorporated herein by reference.

In either embodiment, where there are 2 target sequences, it ispreferable that the first and second effector sequences are bothsubstantially complementary to the one or more target regions of atranscript of their respective target sequences.

Preferably the first and second effector sequences are both selectedfrom any 10 or more and preferably any 17 or more contiguous nucleotideswithin a sequence from the group consisting of SEQ ID NOS: 40-78. Forexample, in one embodiment, there is provided a DNA-directed RNAinterference (ddRNAi) agent for inhibiting expression of one or moretarget sequences in an AMD-associated gene, the ddRNAi agent comprising,in a 5′ to 3′ direction, at least:

-   -   a first effector sequence of any 10 or more contiguous        nucleotides within 5′ UAUGUGGGUGGGUGUGUCUAC 3′ (SEQ ID NO:47);    -   a first effector complement sequence;    -   a second effector sequence any 10 or more contiguous nucleotides        within 5′ AAGUUCAUGGUUUCGGAGGCC 3′ (SEQ ID NO:41) or 5′        UCUUUCUUUGGUCUGCAUUCA 3′ (SEQ ID NO:44); and    -   a second effector complement sequence,        wherein the AMD-associated gene is VEGF-A.

Each effector sequence is substantially complementary to one or moretarget regions in a transcript of the one or more target sequences.

Alternatively, at least one effector, and preferably both effectorsequences, have 100% complementarity to one or more target regions in atranscript of the one or more target sequences.

In particularly preferred embodiments, the first and second effectorsequence comprise any 10 or more, preferably any 17 or more, contiguousnucleotides within sequences able to inhibit the expression of a targetregion by at least 70%. Preferably, in this embodiment, each effectorsequence is selected from SEQ ID NOS: 40-78, more preferably SEQ ID NOS:40-59, and most preferably SEQ ID NOS: 40-49.

In yet another embodiment, being an embodiment where the ddRNAi agenthas 3 effector sequences, there is provided a DNA-directed RNAinterference (ddRNAi) agent for inhibiting expression of one or moretarget sequences in one or more AMD-associated genes, the ddRNAi agentcomprising, in a 5′ to 3′ direction, at least:

-   -   a first effector sequence of any 10 or more contiguous        nucleotides within 5′ AAGUUCAUGGUUUCGGAGGCC 3′ (SEQ ID NO:41);    -   a first effector complement sequence;    -   a second effector sequence of any 10 or more contiguous        nucleotides within 5′ UCUUUCUUUGGUCUGCAUUCA 3′ (SEQ ID NO:44);    -   a second effector complement sequence;    -   a third effector sequence of any 10 or more contiguous        nucleotides within 5′ UAUGUGGGUGGGUGUGUCUAC (SEQ ID NO:47); and    -   a third effector complement sequence,        wherein the AMD-associated gene is VEGF-A.

In yet another embodiment, being an embodiment where the ddRNAi agenthas 2 effector sequences, there is provided a DNA-directed RNAinterference (ddRNAi) agent for inhibiting expression of one or moretarget sequences in one or more AMD-associated genes, the ddRNAi agentcomprising, in a 5′ to 3′ direction, at least:

-   -   a first effector sequence of any 10 or more contiguous        nucleotides within 5′ UGUAACAGAUGAGAUGCUCCA 3′ of the        AMD-associated gene VEGRF-2 (SEQ ID NO:56);    -   a first effector complement sequence;    -   a second effector sequence of any 10 or more contiguous        nucleotides within 5′ UAUGUGGGUGGGUGUGUCUAC 3′ of the        AMD-associated gene VEGFA (SEQ ID NO:47); and    -   a second effector complement sequence.

Each effector sequence in these embodiments is substantiallycomplementary to one or more target regions in a transcript of the oneor more target sequences.

It will be appreciated by the skilled person that the VEGFA sequence canbe first and the VEGFR2 sequence can be second. This is an equivalentembodiment.

In yet another embodiment, being an embodiment where the ddRNAi agenthas 3 effector sequences, there is provided a DNA-directed RNAinterference (ddRNAi) agent for inhibiting expression of one or moretarget sequences in one or more AMD-associated genes, the ddRNAi agentcomprising, in a 5′ to 3′ direction, at least:

-   -   a first effector sequence of any 10 or more contiguous        nucleotides within 5′ AAGUAGCCAGAAGAACAUGGC 3′ of the        AMD-associated gene VEGRF-2 (SEQ ID NO:52);    -   a first effector complement sequence;    -   a second effector sequence of any 10 or more contiguous        nucleotides within 5′ UUAUAGAAAACCCAAAUCCUC 3′ of the        AMD-associated gene CFB (SEQ ID NO:78);    -   a second effector complement sequence;    -   a third effector sequence of any 10 or more contiguous        nucleotides within 5′ UAGCUGAAGCCCACGAGGUCC 3′ of the        AMD-associated gene PDGFR-β (SEQ ID NO:63); and    -   a third effector complement sequence.

Each effector sequence in both of these embodiments is substantiallycomplementary to one or more target regions in a transcript of the oneor more target sequences. It will be appreciated by the skilled personthat the sequence can be in a different 5′ to 3′ order and representequivalent embodiments. For example, PDGFR-β can be first, VEGFR2 can besecond and CFB can be third. Alternatively, at least one effector, andoptionally 2 out of the 3 or all 3 of the effectors, is 100%complementary to one or more target regions in a transcript of the oneor more target sequences.

In particularly preferred embodiments, the first, second and thirdeffector sequence comprise any 10 or more, preferably any 17 or more,contiguous nucleotides within sequences able to inhibit the expressionof a target gene region by at least 70%. Preferably, in this embodiment,each effector sequence is selected from SEQ ID NOS: 40-78, morepreferably SEQ ID NOS: 40-59, and most preferably SEQ ID NOS: 40-49.

In yet further embodiments, the first effector sequence may be any 10 ormore contiguous nucleotides within a sequence selected from the groupconsisting of SEQ ID NOS:40-78; the second effector sequence may be any10 or more contiguous nucleotides within a sequence selected from thegroup consisting of SEQ ID NOS:40-78; the third effector sequence may beany 10 or more contiguous nucleotides within a sequence selected fromthe group consisting SEQ ID NOS:40-78; and any further effectorsequences may be any 10 or more contiguous nucleotides within a sequenceselected from the group consisting of SEQ ID NOS:40-78. Preferably, eacheffector sequence is at least 17 contiguous nucleotides.

Each effector sequence may also be a variant of SEQ ID NOS:40-78, having1, 2, 3, 4 or 5 nucleotide variations. Preferably, the differences arepresent in the first and/or last 5 nucleotides, and at least the centre10-12 nucleotides are 100% complementary to one or more target regionsin a transcript of the one or more target sequences.

The first, second and third effector sequence may each comprise asequence selected from any 10 or more contiguous nucleotides within asequence from the group consisting of SEQ ID NOS: 40-78, oralternatively, each effector sequence may also be a variant of SEQ IDNOS:40-78, having 1, 2, 3, 4 or 5 nucleotide variations. In yet afurther embodiment, each effector sequence may consist of 20nucleotides, of which 17, 18, 19, or all 20 nucleotides are contiguousnucleotides from a sequence selected from the group consisting of SEQ IDNOS: 40-78. When there are multiple effector sequences, they mayrepresent a combination of the 3 types described above.

Furthermore, in the long hairpin structure or the multiple hairpinstructure the ddRNAi agent may include additional effector sequences andcorresponding complementary sequences according to one of the followingformula:

Long Hairpin:

-   -   [effector sequence]₁₋₁₀ [effector complement sequence]₁₋₁₀

Multiple Hairpin:

-   -   [effector sequence-effector complement sequence]₁₋₁₀

Preferably, in the long hairpin formula, the number of effectorsequences is equal to the number of effector complement sequences.Typically, there are 2, 3, 4 or 5 effector sequences, and accordingly,2, 3, 4 or 5 effector complement sequences respectively.

When the ddRNAi agent does contain more than one effector sequence, theeffector sequences may be the same or different. For example, if addRNAi agent has 3 effector sequences, 2 effector sequences may have thesame sequence, while 1 is different. Alternatively, all 3 effectorsequences may be different. Preferably, the effector sequences are any10 or more and preferably any 17 or more contiguous nucleotides within asequence selected from the group consisting of SEQ ID NOS:40-78, orvariants thereof which have 1, 2, 3, 4 or 5 nucleotide variations.Preferably, the differences are present in the first and/or last 5nucleotides, and at least the centre 10-12 nucleotides are 100%complementary to one or more target regions in a transcript of the oneor more target sequences.

When targeting a single region of a target sequence that has naturallyoccurring variants, or single nucleotide polymorphisms, it is preferablythat at least one effector sequence is chosen from any 10 or more andpreferably any 17 or more contiguous nucleotides within a sequenceselected from the group consisting of SEQ ID NOS:40-78, whereas othereffector sequences are variants of that chosen sequence. For example, afirst effector sequence may comprise 20 nucleotides of SEQ ID NO: 47;the second effector sequence should therefore be a variant of SEQ IDNO:47.

Hairpin Structures

In the above embodiments, the effector sequence hybridises with itscorresponding effector complement sequence to form a hairpin structure.At the end of the hairpin, two or more unbound nucleotides form the‘hinge’ or ‘loop’. In one embodiment, the unbound nucleotides are partof the effector sequence and the effector complement, such that only aportion of the at least 17 nucleotides of the effector sequence willform a duplex with its corresponding complementary sequence. Forexample, when the effector sequence and its complement are both 20nucleotides long, 18 of the nucleotides may base pair to form a doublestranded region, leaving a total of 4 nucleotides to form a singlestranded loop between and joining the effector sequence and its effectorcomplement sequence.

In an alternative embodiment, an additional sequence that isnon-complementary to itself, the target sequence, the effector sequenceor the effector complement may be included in the ddRNAi in order tocreate a ‘loop’. As such, in yet another embodiment of the invention,the ddRNAi agent further includes a sequence of 2 to 100 unpairednucleotides capable of forming a loop, more preferably, 2 to 10 unpairednucleotides. In a preferred embodiment the loop includes the nucleotidesequence AA, UU, UUA, UUAG, UUACAA, CAAGAGA or N₁AAN₂, where N₁ and N₂are any of C, G, U and A and may be the same or different. Otherwise,specific loop sequences include ACUGUGAAGCAGAUGGGU. In these loops, notall of the loop sequence has to remain non-annealed. In a loop of, forexample, 18 nucleotides, the first and last 3 nucleotides for examplemay anneal with each other, leaving the intervening 15 nucleotidesnon-annealed.

In embodiments in which the ddRNAi agent is expressed as part of a miRNAstructure the loop sequence may be derived from the miRNA, and isencoded by the miRNA encoding (ME) sequence.

There may be one or more loops depending on the ddRNAi agent structure.When a ddRNAi agent has a structure based on formula [effectorsequence]₁₋₁₀ [effector complement sequence]₁₋₁₀ additionalnon-self-complementary sequence to give rise to a single loop structureis contained between the last effector sequence and the effectorcomplement sequence of that last effector sequence, as illustrated inFIG. 1D. In this embodiment, there is therefore provided a DNA-directedRNA interference (ddRNAi) agent for inhibiting expression of one or moretarget sequences in an AMD-associated gene selected from VEGF-A, VEGFR2,CFB and PDGFR-β, the ddRNAi agent comprising, in a 5′ to 3′ direction,at least:

-   -   a first effector sequence of at least 17 nucleotides in length;    -   a second effector sequence of at least 17 nucleotides in length;    -   a loop sequence of 2 to 100 non-self-complementary nucleotides;    -   a second effector complement sequence; and    -   a first effector complement sequence        wherein each effector sequence is substantially complementary to        one or more target regions in a transcript of the one or more        target sequences.

When the ddRNAi agent has a multiple hairpin structure based on formula[effector sequence-effector complement sequence]₁₋₁₀ additionalnon-self-complementary sequence is contained between each effectorsequence and its complementary sequence to give rise to a loopstructure, as illustrated in FIGS. 1E and F (depending on the type ofexpression cassette used to express it—see later in the specification).In this embodiment, there is provided a DNA-directed RNA interference(ddRNAi) agent for inhibiting expression of one or more target sequencesin an AMD-associated gene, the ddRNAi agent comprising, in a 5′ to 3′direction, at least:

-   -   a first effector sequence of at least 17 nucleotides in length;    -   a loop sequence of 2 to 100 non-self-complementary nucleotides;    -   a first effector complement sequence;    -   a second effector sequence of at least 17 nucleotides in length;    -   a loop sequence of 2 to 100 non-self-complementary nucleotides;        and    -   a second effector complement sequence        wherein each effector sequence is substantially complementary to        one or more target regions in a transcript of the one or more        target sequences in the AMD-associated gene, and gene is        selected from one or more of VEGF-A, VEGFR2, CFB and PDGFR-β.

In this embodiment where there are more than two effector andcomplementary sequences, and therefore more than two hairpin structures,the length of additional non-self-complementary sequence that forms eachloop structure does not have to be the same. For example, one loopstructure may have 5 nucleotides, while another loop structure may have9 nucleotides.

In addition, when there are two or more hairpin structures, there may beadditional non-self-complementary sequence that acts as a spacersequence between each loop. In this embodiment, there is provided aDNA-directed RNA interference (ddRNAi) agent for inhibiting expressionof one or more target sequences in an AMD-associated gene, the ddRNAiagent comprising, in a 5′ to 3′ direction, at least:

-   -   a first effector sequence of at least 17 nucleotides in length;    -   a loop sequence of 2 to 100 non-self-complementary nucleotides;    -   a first effector complement sequence;    -   a spacer sequence of 2 to 100 non-self-complementary        nucleotides;    -   a second effector sequence of at least 17 nucleotides in length;    -   a loop sequence of 2 to 100 non-self-complementary nucleotides;        and    -   a second effector complement sequence        wherein each effector sequence is substantially complementary to        one or more target regions in a transcript of the one or more        target sequences in the AMD-associated gene, and gene is        selected from one or more of VEGF-A, VEGFR2, CFB and PDGFR-β.        2 Strand ddRNAi Agents

As will be appreciated by one skilled in the art, it is not necessarythat the entire ddRNAi agent is expressed as one sequence. For example,in one embodiment of the invention, the first effector sequence may begenerated (e.g., transcribed by one DNA sequence), and the firsteffector complement sequence may be generated (e.g., transcribed from aseparate DNA sequence). Optionally, a loop sequence may be attached toeither transcript or part of the loop attached to the 3′ end of onetranscript and the 5′ end of the other transcript, and that loopsequence may be derived from a miRNA when the effector or effectorcomplement sequence is expressed as part of a miRNA structure. Withinthe cell, the two transcripts then form the ddRNAi agent by hybridisingthrough annealing between the first effector sequences and itscomplement.

In Vitro Expressed ddRNAi Agents of Chemically Synthesised siRNA

While it is envisaged that effective treatment of wet AMD will requireddRNAi agents to be expressed in vivo from ddRNAi constructs (as will beoutlined below), there may be circumstances where it is desirable toadminister ddRNAi agents that are expressed in vitro or to administersiRNAs that are chemically synthesised, thereby functioning as therapywith transient duration of effect. Screening the patient for theirreaction to the treatment for example may benefit from a short termtreatment with siRNAs that do not integrate and replicate in the cellsbefore commencing long term therapy with in vivo expressed ddRNAiagents.

The ddRNAi agents of the invention may therefore be expressed in vitroand then delivered to target cells. Alternatively, siRNAs may bechemically synthesised and then delivered to the target cells. In lightof this, in another aspect of the invention, there is provided a smallinterfering RNAi agent (siRNA agent) for inhibiting expression of one ormore target sequences in an AMD-associated gene, the siRNA comprising

-   -   a first effector sequence of at least 17 nucleotides in length;        and    -   a first effector complement sequence;        wherein the effector sequence is substantially complementary to        one or more target regions in a transcript of the one or more        target sequences.

Similarly to the ddRNAi agents described above, the siRNA agent may alsoinclude more than one effector sequence for multiple targeting, be thatmultiple targets in a single gene such as VEGF-A, or targets in morethan one gene, such as VEGFR2, CFB and PDGFR-β. The effector sequencesare preferably selected from any 10 or more and preferably any 17 ormore contiguous nucleotides within a sequence from the group consistingof SEQ ID NOS: 40-78.

Considerable flexibility is possible in the design of siRNAs. TypicallysiRNAs consist of dsRNA molecules with 5′-phosphate and 3′-hydroxylresidues, strand lengths can vary from 20-29 nucleotides and mayoptionally be designed to include 2 nucleotide 3′ overhangs. In someembodiments each strand can be synthesised as N₁₉₋₂₇TT (where TT can bedeoxyribonucleotides). siRNAs can be readily designed based on regionsof SEQ ID NOS: 40-78 as described above and can be used therapeuticallyas single sequences or in any combinations. Alternatively siRNA agentscan consist of single RNA molecules containing effector and effectorcomplement sequences similar or identical to those expressed from ddRNAiexpression cassettes. These sequences can be based on SEQ ID NOS: 40-78and can be used therapeutically as single sequences or in anycombination with one another. The siRNAs can be chemically synthesizedwith appropriately protected ribonucleoside phosphoramidates and aconventional synthesiser and thus are widely available commercially andable to be designed and synthesised according to routine methods in theart. In preferred embodiments, the siRNAs have the sequences of any 10or more contiguous nucleotides within a sequence from one or more of SEQID NOS: 40-78.

Expression Cassettes and miRNA Backbones

The ddRNAi agents of the invention are expressed from DNA expressioncassettes. The expression cassettes comprise the regulatory sequencesrequired for expression, such as the promoter, together with the DNAsequence that encodes the ddRNAi agent itself. In embodiments in whichthe ddRNAi agent is expressed as part of a miRNA structure, theexpression cassette also includes the DNA sequence that encodes for thatmiRNA structure.

The ddRNAi expression cassettes comprise (in no particular order):

-   -   one of more promoter sequences    -   one or more DNA sequences that encode for one or more effector        sequences    -   one or more DNA sequences that encode for one or more effector        complement sequences;        and optionally    -   one or more terminator sequences    -   one or more DNA sequences that encode for loop sequences, spacer        sequences or both    -   one or more enhancer sequences.

The first promoter sequence and last terminator sequence may be derivedfrom the vector in to which the expression cassette is cloned.

In one embodiment, there is provided a DNA-directed RNA interference(ddRNAi) expression cassette for expressing a ddRNAi agent, wherein theddRNAi agent inhibits expression of one or more target sequences in anAMD-associated gene, the ddRNAi constructs comprising, in a 5′ to 3′direction:

-   -   a promoter sequence    -   a DNA sequence that encodes for a first effector sequence    -   a DNA sequence that encodes for a first effector complement        sequence; and    -   a terminator sequence.

The DNA sequence that encodes for the first effector sequence ispreferably a DNA that encodes for 10 or more, preferably 17 or more,contiguous nucleotides within a sequence from any one of SEQ ID NOS:40-78. In a particularly preferred embodiment, the first effectorsequence comprise any 10 or more, preferably any 17 or more, contiguousnucleotides within sequences able to inhibit the expression of a targetgene region by at least 70%. Preferably, in this embodiment, the firsteffector sequence is selected from SEQ ID NOS: 40-78, more preferablySEQ ID NOS: 40-59, and most preferably SEQ ID NOS: 40-49.

Alternatively, as outlined above in relation to the ddRNAi agent itself,the sequence that encodes for the effector sequence may encode aneffector sequence that varies by 1, 2, 3, 4 or 5 nucleotides from SEQ IDNOS: 40-78 without effecting the ability of the sequence encoded to basepair with the transcript of the target sequence and inhibit expressionof the target sequence.

The skilled person would appreciate that a DNA sequence encoding anygiven RNA sequence is the same sequence as the RNA but having thymine(T) bases instead of uracil (U) bases. The ddRNAi expression cassettesencoding ddRNAi agents having more than one effector sequence in a longhairpin structure comprise, in a 5′ to 3′ direction:

-   -   a promoter sequence;    -   a DNA sequence that encodes for a first effector sequence;    -   a DNA sequence that encodes for a second effector sequence;    -   optionally a sequence that encodes for sequence capable of        forming a loop;    -   a DNA sequence that encodes for a second effector complement        sequence;    -   a DNA sequence that encodes for a first effector complement        sequence; and optionally a terminator sequence.

Preferably the DNA sequences encode first and second effector sequenceselected from any 10 or more and preferably any 17 or more contiguousnucleotides within a sequence from the group consisting of SEQ ID NOS:40-78. Preferably, the first and second effector sequence is selectedfrom SEQ ID NOS: 40-59. Alternatively, the DNA sequences encode for aneffector sequence that varies from SEQ ID NOS: 40-78 by 1, 2, 3, 4 or 5nucleotides without affecting the ability of the effector sequenceencoded to base pair with a transcript of the target sequence andinhibit expression of the target sequence.

When the ddRNAi agent has more than one effector sequence and a multiplehairpin structure based on formula [effector sequence-effectorcomplement sequence]₁₋₁₀ expression of each [effector sequence-effectorcomplement sequence] pair may be controlled by a single promoter, oralternatively by a separate promoter. When separate promoters arecontemplated, the ddRNAi expression cassette comprises, in a 5′ to 3′direction:

-   -   a promoter sequence    -   a DNA sequence that encodes for a first effector sequence    -   a DNA sequence that encodes for a first effector complement        sequence;    -   optionally a terminator sequence;    -   a promoter sequence;    -   a DNA sequence that encodes for a second effector sequence;    -   a DNA sequence that encodes for a second effector complement        sequence; and    -   optionally a terminator sequence.

In this embodiment, multiple ddRNAi agents are produced from the oneexpression cassette, as each effector/effector complement is expressedas a single hairpin structure.

When a single promoter is contemplated, the ddRNAi expression cassettecomprises, in a 5′ to 3′ direction:

-   -   a promoter sequence    -   a DNA sequence that encodes for a first effector sequence    -   a DNA sequence that encodes for a first effector complement        sequence;    -   a DNA sequence that encodes for a second effector sequence;    -   a DNA sequence that encodes for a second effector complement        sequence; and    -   optionally a terminator sequence.

Similarly to the above embodiments, the DNA sequences preferably encodefirst and second effector sequence selected from any 10 or more andpreferably any 17 or more contiguous nucleotides within a sequence fromthe group consisting of SEQ ID NOS:40-78, or, effector sequences thatvary in sequence from SEQ ID NOS: 40-78 by 1, 2, 3, 4 or 5 nucleotides.Preferably, the first and second effector sequence is selected from SEQID NOS: 40-78, more preferably SEQ ID NOS: 40-59, and most preferablySEQ ID NOS: 40-49.

Any of the abovementioned ddRNAi agents are preferably expressed in amiRNA structure from an expression cassette.

Processing of shRNAs expressed from ddRNAi constructs can be imprecise.The expression of the ddRNAi within or as part of an RNA structure likea miRNA, which is a natural substrate for RNAi processing pathways, isone way to minimise this. McBride et al. (2008) designed “artificialmiRNA” constructs which expressed sequences from the base and loop ofendogenous miRNAs; these showed reduced toxicity suggesting more preciseprocessing of expressed shRNAs. Wu et al. (2011) showed that mismatchedduplexes (containing mismatches in the passenger strand) sometimesshowed increased silencing activity, due possibly to their greaterstructural resemblance to endogenous miRNAs. Similarly Gu et al. (2012)showed the introduction of bulges adjacent to loop sequences in shRNAmolecules can result in increased precision of dicer processing.

In embodiments where the effector and effector complement are expressedas a miRNA structure, the ddRNAi expression cassette further includessequence that encodes for the miRNA structure referred to herein as“miRNA encoding sequence” or “ME sequence”. This is the DNA sequencecontained within a ddRNAi expression cassette that encodes for RNAwhich, once expressed, folds in to a miRNA structure. The effectorsequence and the effector complement therefore are expressed as part ofor within that miRNA structure. As will be appreciated from the Figuresillustrating a ddRNAi agent expressed in a miRNA structure, and asdetailed earlier in the specification, the ME sequences will be locatedupstream and downstream of the effector sequence and the effectorcomplement sequence as required. Using an expression cassette thatexpresses a ddRNAi agent with a single effector-effector complement pairas an example, there is provided a DNA-directed RNA interference(ddRNAi) expression cassette for expressing a ddRNAi agent, wherein theddRNAi agent inhibits expression of one or more target sequences in anAMD-associated gene, the ddRNAi cassette comprising, in a 5′ to 3′direction:

-   -   a promoter sequence    -   a first ME sequence    -   a DNA sequence that encodes for a first effector sequence    -   optionally a sequence that encodes for sequence capable of        forming a loop    -   a DNA sequence that encodes for a first effector complement        sequence;    -   a second ME sequence; and    -   optionally a terminator sequence,        wherein the sequence encoded by the first and second ME        sequences is capable of forming a miRNA structure. The effector        sequence and the effector complement therefore are expressed as        part of or within that miRNA structure.

The optional sequence that encodes for sequence capable of forming aloop may also be ME sequence. For example, if a particular miRNAstructure is being utilised as the structure in which the ddRNAi agentis expressed within or as part of, the loop sequence of the ddRNAi agentmay come from the same miRNA. In alternative embodiments, the loopsequence may come from a different miRNA than the miRNA structureencoded by the ME sequences, but nonetheless, is still miRNA derived ororiginating sequence.

The ddRNAi expression cassette may alternatively be described byreference to the total length of the ddRNAi agent expressed, which is aproduct of the total length of sequence between the promoter andterminator. For example, when the length of the effector sequence in asingle effector ddRNAi consists of 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, or 30 nucleotides, the ddRNAi expression cassette willhave a length of 34 to 60 nucleotides between the promoter andterminator. This length may further include 2 to 100 nucleotides of“loop” or “hinge” sequence, giving a length of between 36 to 160nucleotides. For ddRNAi agents having multiple effector sequences, whereeach effector sequence consists of 17, 18, 19, 20, 21, 22, 23, 24, 25,26, 27, 28, 29, or 30 nucleotides, the overall length is increasedproportionally.

The presence of ME sequence for encoding the miRNA structure/s will alsoadd to overall length.

One useful way of designing ddRNAi expression cassettes of the inventionis to assume Dicer cuts every 22 nucleotides (also referred to as ‘22 ntphasing’), and effector sequences can therefore be designed to encodeany 10 or more, and preferably any 17 or more contiguous nucleotideswithin a sequence from the group consisting of SEQ ID NOS:40-78,together with appropriate spacers and other sequence requirements forthe appropriate promoter.

Agents targeting different sites of mRNA are suitable for shRNAconstruction, because they can avoid the influence of secondarystructures of mRNA, and thus perform their functions independently.

When a U6 promoter is used, it is preferable but not essential that theDNA sequence operably linked to the promoter starts with a guanine (G)base; when a H1 promoter is used, it is preferable but not essentialthat the DNA sequence operably linked to the promoter starts with anadenine (A) base. The effector encoding sequence can therefore bemodified accordingly.

The use of miRNA-derived sequences to drive expression of shRNAs isparticularly advantageous when using pol II promoters. Transcriptionalinitiation sites for pol II promoters are frequently imprecise. Sincedicer processing of an shRNA is largely dependent on the structure ofthe shRNA, processing will not be greatly affected by slight variationsin transcriptional start sites in most instances. The use of miRNAderived sequences therefore permits greater flexibility in designingddRNAi constructs that utilise pol II promoters.

In some instances it may be advantageous to increase the length ofshRNAs. One way to accomplish this is to extend the length of theeffector sequence in an shRNA to maximise its complementarity to thetarget sequence, in either a 5′ or 3′ direction, and also extend thelength of the effector complement to maximise base pairing within thestem of the shRNA. For example an shRNA based on SEQ ID NO: 47 could bereadily extended in a 5′ or 3′ direction to target additional sequencesadjacent to those in SEQ ID NO:8 to produce an shRNA with a 30nucleotide stem. The effector sequence could share substantial homologyto the target as defined elsewhere in this specification.

In some instances it may be desirable to avoid the DNA sequence TTTTwithin effector, effector complement or loop sequences since these canact as transcriptional terminators in expression constructs which usePol III promoters such as U6 or H1. shRNA design should also take in toaccount that U6 termination is expected to add a one to five U residuesto the 3′ end to the shRNA. When designing long hairpin RNAs, it issometimes advantageous to modify the precise choice of effectorsequences (either using sequences from, or adjacent to SEQ ID NOS:40-78) to maximise the likelihood that Dicer processed effectorsequences will include a 5′U or A, thereby encouraging incorporationinto AGO2.

The choice of whether to control expression of each [effectorsequence-effector complement sequence] pair with individual promoters ora single promoter depends on a number of factors. A single promoter maybe utilised to minimise interference between promoters. A ddRNAiconstruct with only a single promoter is also smaller in size, which canbe important in some cases for the stability of the construct, bothduring production (e.g. replication in E. coli) and delivery. Inaddition, the use of a single promoter avoids the possibility of anyhomologous recombination between promoters.

In circumstances where a degree of regulation of expression of eacheffector sequence or complement is required though, it is advantageousto design a ddRNAi construct having multiple promoters, wherebyexpression of each [effector sequence-effector complement sequence] pairis controlled by a separate promoter. In circumstances where theeffector sequences are of a different sequence, the nature of thesequence may mean one sequence is expressed to higher expression levels.When it is desired to ensure more equal expression levels of eacheffector sequence, the more highly expressed effector sequence can bepaired with a weaker promoter and vice versa. Moreover, more efficientexpression may be achieved as the length of any one sequence to betranscribed is shorter particularly for pol III promoters. When multiplepromoters are used, it is preferable that not all of the promoters arethe same to minimise the risk of any homologous recombination betweenthem in the expression cassette. In the case of 2 promoters, each ispreferably different. In the case of 3 promoters, at least 2 andoptionally all 3 are different from one another.

The DNA sequence encoding the effector sequence is operably linked tothe promoter sequence. A sequence is “operably linked” to anothernucleotide sequence when it is placed in a functional relationship withanother nucleotide sequence. For example, if a coding sequence isoperably linked to a promoter sequence, this generally means that thepromoter may promote transcription of the coding sequence. Operablylinked means that the DNA sequences being linked are typicallycontiguous and, where necessary to join two protein coding regions,contiguous and in reading frame. However, since enhancers may functionwhen separated from the promoter by several kilobases and intronicsequences may be of variable length, some nucleotide sequences may beoperably linked but not contiguous.

A “promoter” or “promoter sequence” or “promoter element” is generally aDNA regulatory region capable of binding RNA polymerase in a cell andinitiating transcription of a polynucleotide or polypeptide codingsequence such as mRNA or any kind of RNA transcribed by any class of anyRNA polymerase. The promoter and terminator may be taken from differentgenes, but are typically matched to each other; that is, the promoterand terminator elements are taken from the same gene in which they occurnaturally. Promoters also may or may not be modified using moleculartechniques, or otherwise, e.g., through modification of regulatoryelements, to attain weaker or stronger levels of transcription.

The term “constitutive” when made in reference to a promoter means thatthe promoter is capable of directing transcription of an operably linkednucleic acid sequence in the absence of a specific stimulus (e.g., heatshock, chemicals, light, etc.). Typically, constitutive promoters arecapable of directing expression of a coding sequence in substantiallyany cell and any tissue. The promoters used to transcribe the ddRNAiagents preferably are constitutive promoters, such as the promoters forubiquitin, CMV, β-actin, histone H4, EF-1alfa or pgk genes controlled byRNA polymerase II, or promoter elements controlled by RNA polymerase I.In other embodiments, a Pol II promoter such as CMV, SV40, U1, hAAT,β-actin or a hybrid Pol II promoter is employed. In other embodiments,promoter elements controlled by RNA polymerase III are used, such as theU6 promoters (e.g. U6-1, U6-8, U6-9), H1 promoter, 7SL promoter, thehuman Y promoters (hY1, hY3, hY4 (see Maraia et al., (1994)) and hY5(see Maraia et al., (1994)), the human MRP-7-2 promoter, Adenovirus VA1promoter, human tRNA promoters, the 5S ribosomal RNA promoters, as wellas functional hybrids and combinations of any of these promoters.Variants of all of these promoters may also be utilised, wherein thepromoter is modified to decrease or increase its activity. For example,if a strong promoter causes too much expression of the sequence operablylinked to it, it can be modified to decrease its activity.

When a U6 promoter is used, it is preferable that the DNA sequenceoperably linked to the promoter starts with a guanine (G) base; when aH1 promoter is used, it is preferable that the DNA sequence operablylinked to the promoter starts with an adenine (A) base. The sequences ofthe nucleic acids may therefore favour the use of one promoter overanother.

Alternatively in some embodiments it may be optimal to select promotersthat allow for inducible expression of the multiple ddRNAi agentsexpressed from the ddRNAi construct. A number of systems for inducibleexpression using such promoters are known in the art, including but notlimited to the tetracycline responsive system and the lacoperator-repressor system (see WO 03/022052 A1 Publication; and U.S.Patent Publication 2002/0162126 A1), the ecdyson regulated system, orpromoters regulated by glucocorticoids, progestins, estrogen, RU-486,steroids, thyroid hormones, cyclic AMP, cytokines, the calciferol familyof regulators, or the metallothionein promoter (regulated by inorganicmetals such as zinc or cadmium).

Promoters useful in some embodiments of the present invention may betissue-specific or cell-specific. The term “tissue-specific” as itapplies to a promoter refers to a promoter that is capable of directingselective expression of a nucleotide sequence of interest to a specifictype of tissue in the relative absence of expression of the samenucleotide sequence of interest in a different type of tissue (e.g.,brain). The term “cell-specific” as applied to a promoter refers to apromoter which is capable of directing selective expression of anucleotide sequence of interest in a specific type of cell in therelative absence of expression of the same nucleotide sequence ofinterest in a different type of cell within the same tissue The term“cell-specific” when applied to a promoter also means a promoter capableof promoting selective expression of a nucleotide sequence of interestin a region within a single tissue. Alternatively, promoters may beconstitutive or regulatable. Additionally, promoters may be modified soas to possess different specificities.

Examples of cell specific promoters particularly useful in thisinvention include the RPE cell specific promoter RPE-65 and VMD2, andthe choroid endothelial-specific promoters FLT-1 or ICAM2.

As noted above, enhancer elements are optionally included in the ddRNAiconstructs of the invention.

When the ddRNAi expression cassette or construct contains more than oneterminator sequence or element, the terminator sequences or elements maybe the same, or different, or there may be a combination of terminationelements represented only once and termination elements represented twotimes or more within any cassette. Whatever terminator sequences orelements are used they should be selected to ensure that they workappropriately with the liver-specific promoter used. In instances wherePol I, Pol II or Pol III promoters are used, appropriate terminatorsequences should be employed. Termination elements useful in the presentinvention include the U1 termination sequence (U1 box), the syntheticpolyA terminator, and the so called minimal PolyA terminator.Transcriptional pause sites, such as MAZ1 and MAZ2, (See Ashfield et alEMBO J 1994 Vol13 No 23 5656 pp and Yonaha and Proudfoot EMBO J. 2000Jul. 17; 19(14):3770-7) may be inserted upstream of the polyAterminators to assist in coupling of transcription termination andpolyadenylation. For Pol III promoters, the sequences TTTT, TTTTT orTTTTTT are commonly used as terminators. In these instances transcriptsare typically terminated by the sequence UU.

ddRNAi Agent Expression Constructs

ddRNAi agents may be expressed from a DNA expression cassette insertedinto any suitable vector or ddRNAi construct, referred to herein as‘ddRNAi constructs’. A challenge in the past to developing therapeuticsfor AMD has been efficient and uniform transduction of the correct cellsto ensure long term expression without the need for recurringadministrations.

When the vector backbone of the construct is compatible with a deliverysystem, the ddRNAi expression constructs are also delivery constructs. Aparticularly preferred delivery construct is a viral vector. Use of aviral vector, like an adeno-associated virus (AAV), adenovirus (Ad) orlentivirus (LV) to deliver an expression construct that produces thetherapeutic ddRNAi agent from within the cell, avoids an interferonresponse often caused by direct interactions of nucleic acids withsurface-expressed toll-like receptor 3. This is a primary reason for anumber of failures of siRNA-based ocular drugs in clinical trials.

In the case of the current invention, the ddRNAi agent of the inventionis required to reach the retina pigment epithelial (RPE) cells or othercells deep within the retinal layers. To this effect, the inventionutilizes a modified adeno-associated virus (AAV) vector, shown in murinemodels to be able to penetrate the RPE layer following intravitrealinjection. Wildtype, unmodified AAV serotypes have limited ability totransduce more than the adjoining layer of cells when introduced intothe eye through this route. For this reason, it is preferred that amodified AAV vector is utilised in the invention.

For example, site directed mutagenesis of AAV strains has been used tosubstitute tyrosine residues, leading to increased transduction (LiZhong, Baozheng Li, Cathryn S. Mah, (2008) Proc Natl Acad Sci USA.105(22): 7827-7832). Similar modifications to AAV vectors have producedvectors that can transduce across all layers of the retina followingintravitral injection (Hilda Petrs-Silva, Astra Dinculescu, Qiuhong Liet al. (2009) Mol Ther. 17(3): 463-471). Likewise, specific serine,threonine or lysine residues in AAV vectors have been modified to avoidthe host cellular kinase/ubiquitination/proteasomal machinery andsignificantly increase transduction efficiency (Gabriel N, Hareendran S,Sen D et al. (2013) Hum Gene Ther Methods. 2013 (2):80-93). Methods thatgenerate libraries of AAV capsid mutants can be screened to isolatevariants with the desired properties of increased tissue specificity fora specific target tissue or reduced immunogenicity. Recently, Schafferet al have been able to show broad transretinal delivery followingintravitreal injection of an AAV mutated vector in which a 7mer peptidehad been inserted into the capsid sequence (Dalkara, D., L. C. Byrne, R.R. Klimczak et al. (2013) Science Translational Medicine, 5:189ra76)

Typically, the genome of AAV contains only two genes. The “rep” genecodes for at least four separate proteins utilized in DNA replication.The “cap” gene product is spliced differentially to generate the threeproteins that comprise the capsid of the virus. When packaging thegenome into nascent virus, only the Inverted Terminal Repeats (ITRs) areobligate sequences; rep and cap can be deleted from the genome and bereplaced with heterologous sequences of choice. However, in order toproduce the proteins needed to replicate and package the AAV-basedheterologous construct into nascent virions, the rep and cap proteinsmust be provided in trans. The helper functions normally provided byco-infection with the helper virus, such as adenovirus or herpesvirus,can also be provided in trans in the form of one or more DNA expressionplasmids. Since the genome normally encodes only two genes it is notsurprising that, as a delivery vehicle, AAV is limited by a packagingcapacity of 4.5 single stranded kilobases (kb). However, although thissize restriction may limit the genes that can be delivered forreplacement gene therapies, it does not adversely affect the packagingand expression of shorter sequences such as ddRNAi vectors.

The invention provides a ddRNAi expression construct comprising a ddRNAiexpression cassette according for expressing a ddRNAi agent forinhibiting expression of one or more target sequences in an AMDassociated gene, the expression cassette comprising (in no particularorder)

-   -   one or more promoter sequences    -   one or more DNA sequences that encode for one or more effector        sequences,    -   one or more DNA sequences that encode for one or more effector        complement sequences;    -   and optionally    -   one or more terminator sequences    -   one or more DNA sequences that encode for loop sequences, spacer        sequences, or both    -   one or more enhancer sequences,        wherein the construct is a viral delivery construct; preferably        the viral delivery construct is an AAV modified vector.

Preferably the expression cassette further comprises ME sequence so thatthe ddRNAi agent is expressed as part of or within a miRNA structure.

In a preferred embodiment, the expression cassette of the viral deliveryconstruct comprises two DNA sequences that encode a first effectorsequence of any 10 or more contiguous nucleotides within 5′UGUAACAGAUGAGAUGCUCCA 3′ of the AMD-associated gene VEGRF-2 (SEQ IDNO:56) and a second effector sequence of any 10 or more contiguousnucleotides within 5′ UAUGUGGGUGGGUGUGUCUAC 3′ of the AMD-associatedgene VEGF-A (SEQ ID NO:47).

The expression of the ddRNAi agents of the invention following viraldelivery will be durable, potentially up to the life of a patient, froma single administration of the drug. Accordingly, in another aspect ofthe invention, there is provided a ddRNAi therapeutic comprising a viralvector into which a ddRNAi expression cassette according to theinvention is inserted. Preferably the expression cassette encodes formultiple ddRNAi agents, as either long hairpin structures or multiplehairpin structures selected from the combinations and embodimentsdescribed throughout the specification. In a preferred embodiment, theeffector sequences and the effector complement sequences of the ddRNAiagents are expressed within a miRNA structure.

Typically, in the production of viral vectors, the normal endogenousgenes of a virus can be deleted from the genome and be replaced withheterologous sequences of choice. However, in order to produce theproteins needed to replicate and package the virus-based heterologousconstruct into nascent virion, the viral proteins stripped from thegenome must be provided in trans. Generation of the construct can beaccomplished using any suitable genetic engineering techniques wellknown in the art, including without limitation, the standard techniquesof PCR, oligonucleotide synthesis, DNA synthesis, restrictionendonuclease digestion, ligation, transformation, plasmid purification,and DNA sequencing. The viral construct also may contain genes thatallow for replication and propagation of virus, though in preferredembodiments such genes will be supplied in trans. Additionally, theddRNAi construct may contain genes or genetic sequences from the genomeof any known organism incorporated in native form or modified. Forexample, the preferred viral construct comprises sequences useful forreplication of the construct in bacteria.

After generation of the viral based ddRNAi construct, the construct ispackaged into viral particles. Any method known in the art may be usedto produce infectious viral particles whose genome comprises a copy ofthe viral ddRNAi construct. One method utilizes packaging cells thatstably express in trans the viral proteins that are required for theincorporation of the viral ddRNAi construct into viral particles, aswell as other sequences necessary or preferred for a particular viraldelivery system (for example, sequences needed for replication,structural proteins and viral assembly) and either viral-derived orartificial ligands for tissue entry. Following transfection of the viralddRNAi construct into packaging cells, the packaging cells thenreplicate viral sequences, express viral proteins and package the ddRNAiexpression constructs into infectious viral particles. The packagingcell line may be any cell line that is capable of expressing viralproteins, including but not limited to 293, HeLa, A549, PerC6, D17,MDCK, BHK, bing cherry, phoenix, Cf2Th, or any other line known to ordeveloped by those skilled in the art. One packaging cell line isdescribed, for example, in U.S. Pat. No. 6,218,181.

Alternatively, a cell line that does not stably express necessary viralproteins may be co-transfected with one or more constructs to achieveefficient production of functional particles. One of the constructs isthe viral based ddRNAi construct; the other construct comprises nucleicacids encoding the proteins necessary to allow the cells to producefunctional virus as well as other helper functions.

The packaging cell line or replication and packaging construct may notexpress envelope gene products. In these embodiments, the gene encodingthe envelope gene can be provided on a separate construct that isco-transfected with the viral based ddRNAi construct. As the envelopeprotein is responsible, in part, for the host range of the viralparticles, the viruses may be pseudotyped. As described supra, a“pseudotyped” virus is a viral particle having an envelope protein thatis from a virus other than the virus from which the genome is derived.One with skill in the art can choose an appropriate pseudotype for theviral delivery system used and cell to be targeted.

In addition to conferring a specific host range, a chosen pseudotype maypermit the virus to be concentrated to a very high titer. Virusesalternatively can be pseudotyped with ecotropic envelope proteins thatlimit infection to a specific species (e.g., ecotropic envelopes allowinfection of, e.g., murine cells only, where amphotropic envelopes allowinfection of, e.g., both human and murine cells). In addition,genetically-modified ligands can be used for cell-specific targeting.

After production in a packaging cell line, the viral particlescontaining the ddRNAi expression cassettes are purified and quantified(titred). Purification strategies include density gradientcentrifugation, or, preferably, column chromatographic methods.

Methods

Administration of ddRNAi agents, ddRNAi constructs of siRNA agents ofthe invention inhibits expression of genes expressed in cells within theretina. Accordingly, in another aspect of the invention, there isprovided a method of treating AMD in an individual comprising theadministration of a therapeutically effective amount of a ddRNAiconstruct to a patient in need of treatment, wherein the ddRNAi agentinhibits expression of one or more target sequences in an AMD-associatedgene, preferably a VEGF-A gene. Preferably, the AMD to be treated is wetAMD.

The ddRNAi agent to be administered to the patient may be one or moreof:

-   -   ddRNAi agent comprising a first effector sequence; and a first        effector complement sequence; wherein the effector sequence is        substantially complementary to one or more target regions in a        transcript of the one or more target sequences    -   ddRNAi agent comprising, in a 5′ to 3′ direction, a first        effector sequence; a second effector sequence; a second effector        complement sequence; and a first effector complement sequence,        wherein each effector sequence is substantially complementary to        one or more target regions in a transcript of the one or more        target sequences    -   a ddRNAi agent comprising, in a 5′ to 3′ direction, a first        effector sequence; a second effector sequence; a third effector        sequence; a third effector complement sequence; a second        effector complement sequence; and a first effector complement        sequence wherein each effector sequence is substantially        complementary to one or more target regions in a transcript of        the one or more target sequences    -   a ddRNAi agent comprising, in a 5′ to 3′ direction, a first        effector sequence; a first effector complement sequence; a        second effector sequence; and a second effector complement        sequence wherein each effector sequence is substantially        complementary to one or more target regions in a transcript of        the one or more target sequences    -   a ddRNAi agent comprising, in a 5′ to 3′ direction, a first        effector sequence; a first effector complement sequence; a        second effector sequence; a second effector complement sequence;        a third effector sequence; and a third effector complement        sequence; wherein each effector sequence is substantially        complementary to one or more target regions in a transcript of        the one or more target sequences    -   a ddRNAi agent comprising, in a 5′ to 3′ direction, a first        effector sequence; a second effector sequence; a loop sequence        of 2 to 100 non-self-complementary nucleotides; a second        effector complement sequence; and a first effector complement        sequence wherein each effector sequence is substantially        complementary to one or more target regions in a transcript of        the one or more target sequences    -   a ddRNAi agent comprising, in a 5′ to 3′ direction, a first        effector sequence; a loop sequence of 2 to 100        non-self-complementary nucleotides; a first effector complement        sequence; a second effector sequence; a loop sequence of 2 to        100 non-self-complementary nucleotides; and a second effector        complement sequence wherein each effector sequence is        substantially complementary to one or more target regions in a        transcript of the one or more target sequences    -   a ddRNAi agent comprising, in a 5′ to 3′ direction, a first        effector sequence; a loop sequence of 2 to 100        non-self-complementary nucleotides; a first effector complement        sequence; a spacer sequence of 2 to 100 non-self-complementary        nucleotides; a second effector sequence; a loop sequence of 2 to        100 non-self-complementary nucleotides; and a second effector        complement sequence wherein each effector sequence is        substantially complementary one or more target regions in a        transcript of the one or more target sequences    -   a ddRNAi agent comprising, in a 5′ to 3′ direction, a first        effector sequence; a first effector complement sequence; a        spacer sequence of 2 to 100 non-self-complementary nucleotides;        a second effector sequence; a second effector complement        sequence; a spacer sequence of 2 to 100 non-self-complementary        nucleotides; a third effector sequence; and a third effector        complement sequence    -   any of the above mentioned ddRNAi agents expressed within or as        part of an miRNA structure.

As would be understood by one skilled in the art, and as illustrated inthe Figures, any particular effector sequence may be swapped in positionwith its complement in the ddRNAi agent. In particular forms of each ofthe embodiments described above, each effector sequence is at least 17nucleotides in length selected from the group consisting of any 10 ormore and preferably any 17 or more contiguous nucleotides within asequence from any one of SEQ ID NOS: 40-78. The effector sequences mayall be the same, or may all be different, or may be a combination e.g. 2effector sequences of at least 10 contiguous nucleotides of SEQ ID NO:47and 1 effector sequence of at least 10 contiguous nucleotides of (forexample) SEQ ID NO: 56.

Preferably, the effector sequence is selected from the group consistingof any contiguous 11, 12, 13, 14, 15 or 16 nucleotides within any one ofSEQ ID NOS: 40-78, and most preferably 17 or more contiguous nucleotideswithin any one of SEQ ID NOS: 40-78. Typically, the effector complementwill be the same length, or about the same length (ie ±15% nucleotidelength, or 1 to 3 nucleotides different depending on the overall length)as its corresponding effector sequence.

Each of these ddRNAi agents may be administered via a ddRNAi expressioncassette in a ddRNAi construct, as described in the earlier sections ofthe specification. Preferably the ddRNAi construct is the AAV basedconstruct to enable targeting of the construct to the RPE cells in theback of the eye. Multiple targeting may be achieved by delivering two ormore ddRNAi expression cassettes or constructs each capable ofexpressing a single ddRNAi agent, or alternatively, and most preferably,by delivering one ddRNAi expression cassettes or constructs capable ofexpressing more than one ddRNAi agent.

In alternative embodiments, each of the effector sequences may be 100%complementary to one or more target regions in a transcript of the oneor more target sequences, or may only vary by 1, 2, 3, 4 or 5nucleotides.

The method of treating AMD can optionally include a preliminary step ofidentifying an individual having symptoms of AMD and requiringtreatment. That identification step can include differentiallydiagnosing the subject as having wet AMD or dry AMD.

For longer term or stable provision of the ddRNAi agents of theinvention, the ddRNAi agent is provided via a ddRNAi construct of theinvention ie in vivo expression of the ddRNAi agent from a ddRNAiexpression cassette inserted into a suitable vector delivered to thecell. The ddRNAi expression cassette comprises:

-   -   one or more promoter sequences    -   one or more DNA sequences selected from the group consisting of        sequences that encode for any 10 or more contiguous nucleotides        within a sequence from SEQ ID NOS: 40-78;    -   one or more DNA sequences that encode for one or more effector        complement sequences;    -   and optionally    -   one or more terminator sequences    -   one or more DNA sequences that encode for loop sequences, spacer        sequences or both    -   one or more enhancer sequences.

As outlined earlier in the specification, these components of the ddRNAiexpression cassette may have different 5′ to 3′ arrangements, all ofwhich are suitable for use in the methods of the invention. Theexpression cassette preferably also includes DNA sequences that encodesequence capable of forming a miRNA structure.

Preferably, the target AMD-associated gene in the methods of theinvention is VEGF-A. Accordingly, in one embodiment of the invention,the ddRNAi agent inhibits expression of one or more target sequences inthe VEGF-A gene. The DNA sequence that encodes for the first effectorsequence is preferably selected from the ddRNAi effector encodingsequences of any 10 or more contiguous nucleotides within a sequencefrom SEQ ID NOS: 40-49 listed in Table 1. Alternatively, as detailedearlier, the sequence that encodes for the effector sequence may varyfrom SEQ ID NOS: 40-49 by 1, 2, 3, 4 or 5 nucleotides without effectingthe ability of the sequence encoded to base pair with the targetsequence and inhibit expression of the VEGF-A target sequence.

Typically, each effector sequence forms a double stranded region withthe corresponding effector complement sequence.

In an alternative embodiment, the target AMD-associated gene in themethods of the invention is one or more of VEGFR2, CFB and PDGFR-β.

In an alternative embodiment, the method of treating AMD in anindividual comprises the administration of a therapeutically effectiveamount of a ddRNAi construct that encodes a ddRNAi agent having morethan one effector sequence, such as those listed above as SEQ ID NOS:40-78, for inhibiting, preventing or reducing expression of one or moretarget sequences in an AMD associated gene.

In any of the treatment methods of the invention, the patient may alsobe receiving other treatments, such that the ddRNAi constructadministered is an adjunct therapy.

AMD, and wet AMD in particular, is characterised by an abnormaloutgrowth of blood vessels from the vasculature situated behind theretina in a process that is often referred to as choroidalneovascularization (CNV). Controlling CNV therefore has a positiveeffect on patients suffering from wet AMD. Accordingly, another aspectof the invention is a method of treating choroidal neovascularization inan individual comprising the administration of a therapeuticallyeffective amount of a ddRNAi agent, expression cassette or construct ofthe invention to a patient in need of treatment, wherein the ddRNAiagent inhibits expression of one or more target sequences in one or moreof VEGF-A, VEGFR2, CFB and PDGFR-β. Each of these genes is a target ofinterest by virtue of their role in angiogenesis, neovascularisation orthe VEGF pathway.

Another important factor in the pathogenesis of AMD is the formation ofextracellular deposits at the base of the eye called drusen. Thesedeposits contribute to distortion of the macular and may also play arole in neovascularisation. CFB is a component of drusen. As such,targeting the CFB gene to inhibit expression of its protein product canreduce the amount of drusen being deposited, therefore having a positiveeffect on patients suffering from AMD. There is therefore provided amethod of reducing drusen deposits in an individual comprising theadministration of a therapeutically effective amount of a ddRNAi agent,expression cassette or construct of the invention to a patient in needof treatment, wherein the ddRNAi agent inhibits expression of one ormore target sequences in CFB.

Seeking to minimise angiogenesis and therefore CNV, together withseeking to inhibit drusen deposition by way of targeting combinations ofVEGF-A, VEGFR2, CFB and PDGFR-β therefore provides a multi-prongedattack strategy for AMD, particularly wet AMD, that has not beenpreviously contemplated in the art, and seeks to not only stopprogression of AMD, but to restore visual acuity.

In some instances, it may be preferred to rely on the transient presenceof a ddRNAi agent or siRNA agent as opposed to long term expression ofddRNAi agents from integrated or stably maintained ddRNAi constructs.For example, where the patient's tolerance to the treatment is to bedetermined first. In this instance, a ddRNAi agent or siRNA agent of theinvention produced in vitro may be administered.

In a further aspect of the invention there is provided a compositioncomprising ddRNAi constructs, ddRNAi agents or siRNA agents as an activeingredient for inhibiting, preventing or reducing expression of one ormore target sequences in an AMD associated gene, to treat AMD, treatCNV, minimise drusen deposition or alleviate the symptoms of AMD.

In a further aspect of the invention there is provided use of a ddRNAiconstruct, ddRNAi agent or siRNA agent for inhibiting, preventing orreducing expression of one or more target sequences in an AMD associatedgene, to treat AMD, treat CNV, minimise drusen deposition or alleviatethe symptoms of AMD. Similarly, there is provided use a ddRNAiconstruct, ddRNAi agent or siRNA agent in the preparation of amedicament for inhibiting, preventing or reducing expression of one ormore target sequences in an AMD associated gene, to treat AMD, treatCNV, minimise drusen deposition or alleviate the symptoms of AMD.

Preferably the AMD is wet AMD.

The one or more effector sequences of the ddRNAi constructs, ddRNAiagents or siRNA agents used in the methods of the invention comprise any10 or more, preferably any 17 or more, contiguous nucleotides withinsequences able to inhibit the expression of the AMD-associated targetgene region by at least 70%. Preferably the one or more effectorsequence is selected from SEQ ID NOS: 40-78, more preferably SEQ ID NOS:40-59, and most preferably SEQ ID NOS: 40-49.

In each of the methods of the invention, the ddRNAi agent, ddRNAiexpression cassette or ddRNAi expression construct of the invention ispreferably delivered to the subject's eye/s by intravitreal injection,although subretinal injection may also be utilised.

Pharmaceutical Compositions

The ddRNAi agents, the siRNA agents or the vectors comprising ddRNAiexpression cassettes of the invention can be formulated intopharmaceutical compositions by combination with appropriate,pharmaceutically acceptable carriers or diluents. Accordingly, there isprovided a pharmaceutical composition comprising a ddRNAi agent, addRNAi expression cassette, a ddRNAi construct or a siRNA agent of theinvention for inhibiting, preventing or reducing expression of one ormore target sequences in an AMD associated gene, and a pharmaceuticallyacceptable carrier or diluent.

In another embodiment the invention provides an AMD treatmentcomposition comprising an effective amount of a ddRNAi agent, ddRNAiexpression cassette or ddRNAi expression construct of the invention as amain ingredient for inhibiting, preventing or reducing expression of oneor more target sequences in an AMD associated gene, optionally with apharmaceutically acceptable carrier or diluent.

In pharmaceutical dosage forms, the agents or the vectors comprising theddRNAi expression cassettes may be administered alone or in associationor combination with other pharmaceutically active compounds. Those withskill in the art will appreciate readily that dose levels for agents orvectors comprising the ddRNAi expression cassettes will vary as afunction of the nature of the delivery vehicle, the relative ease oftransduction of the target cells, the expression level of the RNAiagents in the target cells and the like.

The ddRNAi agents, the siRNA agents or the vectors comprising ddRNAiexpression cassettes of the invention can be formulated intopreparations for injection or administration by dissolving, suspendingor emulsifying them in an aqueous or non-aqueous solvent, such as oils,synthetic aliphatic acid glycerides, esters of higher aliphatic acids orpropylene glycol; and if desired, with conventional additives such assolubilisers, isotonic agents, suspending agents, emulsifying agents,stabilizers and preservatives.

The most preferred mode of administration of the pharmaceuticalcomposition of the invention to the subject's eye/s is by intravitrealinjection. An alternative method of administration is subretinalinjection.

Pharmaceutically acceptable carriers or diluents contemplated by theinvention include any diluents, carriers, excipients, and stabilizersthat are nontoxic to recipients at the dosages and concentrationsemployed, and include buffers such as phosphate, citrate, and otherorganic acids; antioxidants including ascorbic acid and methionine;preservatives (such as octadecyldimethylbenzyl ammonium chloride;hexamethonium chloride; benzalkonium chloride, benzethonium chloride;phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propylparaben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol);low molecular weight (less than about 10 residues) polypeptides;proteins, such as plasma albumin, gelatin, or immunoglobulins;hydrophilic polymers such as polyvinylpyrrolidone; amino acids such asglycine, glutamine, asparagine, histidine, arginine, or lysine;monosaccharides, disaccharides, and other carbohydrates includingglucose, mannose, or dextrins; chelating agents such as EDTA; sugarssuch as sucrose, mannitol, trehalose or sorbitol; salt-formingcounter-ions such as sodium; metal complexes (e.g. Zn-proteincomplexes); and/or non-ionic surfactants such as TWEEN™, PLURONICS™ orpolyethylene glycol (PEG).

In general the formulations are prepared by uniformly and intimatelybringing into association the active ingredient with liquid carriers orfinely divided solid carriers or both, and if necessary, shaping theproduct. Formulation may be conducted by mixing at ambient temperatureat the appropriate pH, and at the desired degree of purity, withphysiologically acceptable carriers, i.e., carriers that are non-toxicto recipients at the dosages and concentrations employed.

The one or more effector sequences of the ddRNAi constructs, ddRNAiagents or siRNA agents used in the compositions of the inventioncomprise any 10 or more, preferably any 17 or more, contiguousnucleotides within sequences able to inhibit the expression of theAMD-associated target gene region by at least 70%. Preferably the one ormore effector sequence is selected from SEQ ID NOS: 40-78, morepreferably SEQ ID NOS: 40-59, and most preferably SEQ ID NOS: 40-49.

In another embodiment there is provided a kit or article of manufactureincluding an RNAi agent or pharmaceutical composition as describedabove.

In other embodiments there is provided a kit for use in a therapeuticapplication mentioned above, the kit including:

-   -   a container holding a RNAi agent or pharmaceutical composition;    -   a label or package insert with instructions for use.

In certain embodiments the kit may contain one or more further activeprinciples or ingredients for treatment of AMD or for treating anAMD-related condition as described above.

The kit or “article of manufacture” may comprise a container and a labelor package insert on or associated with the container. Suitablecontainers include, for example, bottles, vials, syringes, blister pack,etc. The containers may be formed from a variety of materials such asglass or plastic. The container holds an RNAi agent or pharmaceuticalcomposition which is effective for treating the condition and may have asterile access port (for example the container may be an intravenoussolution bag or a vial having a stopper pierceable by a hypodermicinjection needle). The label or package insert indicates that the RNAiagent or pharmaceutical composition is used for treating the conditionof choice. In one embodiment, the label or package insert includesinstructions for use and indicates that the RNAi agent or pharmaceuticalcomposition can be used to treat AMD or for treating a AMD-relatedcondition as described above.

The kit may comprise (a) an RNAi agent or pharmaceutical composition;and (b) a second container with a second active principle or ingredientcontained therein. The kit in this embodiment of the invention mayfurther comprise a package insert indicating that the RNAi agent orpharmaceutical composition and other active principle can be used totreat AMD or for treating an AMD-related condition as described above.Alternatively, or additionally, the kit may further comprise a second(or third) container comprising a pharmaceutically-acceptable buffer,such as bacteriostatic water for injection (BWFI), phosphate-bufferedsaline, Ringer's solution and dextrose solution. It may further includeother materials desirable from a commercial and user standpoint,including other buffers, diluents, filters, needles, and syringes.

In certain embodiments an RNAi agent or pharmaceutical composition maybe provided in the form of a device, disposable or reusable, including areceptacle for holding the RNAi agent or pharmaceutical composition. Inone embodiment, the device is a syringe, preferably a syringe suitablefor intravitreal injection or subretinal injection. The device may hold1-2 mL of the RNAi agent or pharmaceutical composition. The RNAi agentor pharmaceutical composition may be provided in the device in a statethat is ready for use or in a state requiring mixing or addition offurther components.

The invention is now described with reference to the followingnon-limiting examples.

EXAMPLES 1. Design and Preparation of Constructs to Silence VEGF-A

ddRNAi constructs expressing shRNAs targeting VEGF-A were designed, torecognise RNAi target sequences in the VEGF-A mRNA that are wellconserved between human and the pre-clinical test species mouse andmacaque. 10 ddRNAi constructs (miR-1, miR-2, miR-3, miR-4, miR-5, miR-6,miR-7, miR-8, miR-9 and miR-10) were generated to express the effectorsequences listed in Table 2. Oligonucleotides were synthesised (SigmaAldrich) and assembled to produce BamHI/Hind III fragments that wascloned into the BamHI/Hind III sites of pSilencer 2.1-U6 hygro accordingto the manufacture's protocol (Invitrogen). These constructs used thehuman U6 promoter to drive expression of shRNAs. Maps of the vector andan insert for one such construct are shown In FIGS. 2A and 2B. Thesequence of the insert and predicted secondary structure of theexpressed shRNA for miR-8 are shown in FIGS. 2C and 2D. Sequences of theBamHI/Hind III fragments used to prepare miRs-1 to 10 are listed as SEQID NOS: 91-100.

2. Activity and Strand-Specificity of Constructs Targeting VEGF-A

Dual luciferase assays were used to determine the activity of miRconstructs. Because firefly luciferase has a relatively short half-lifeof approximately four hours, measurement of firefly luciferase activityprovides a surrogate marker for assessing RNAi inhibitory activity. Forthese experiments, sensor constructs containing regions of VEGF-A cDNAwere cloned into the 3′ UTR of a firefly luciferase expression constructpGL3 (Promega). Regions of a VEGF-A cDNA clone, obtained from OpenBiosystems (a Thermo Scientific company), were amplified by PCR usingmethods well known in the art, to prepare fragments flanked by XbaI andFseI restriction sites; these amplified fragments were then cloned intothe XbaI/FseI sites in the 3′ UTR of pGL3. Five separate regions ofVEGF-A were amplified in this way to prepare reporter constructs thatcould be used to assay miR 1-10, as shown in Table 3. These five regions(A to E, Table 3) were cloned in both orientations which allowed thestrand preference of RISC loading to be determined. “Sense” reporterconstructs assayed activity of passenger strands, while reporters termed“antisense” assayed activity of effector strands. ddRNAi constructs withstrong effector activity and weak passenger activity are stronglyfavoured for therapeutic use since, as discussed above, since these arelikely to produce less off target effects.

To assay the activity and strand-preference of each of the miRconstructs targeting VEGF-A, dual luciferase assays were performedaccording to manufacturer's (Promega) protocol. Briefly a specificddRNAi construct was co-transfected along with the appropriate VEGF-Asensor and a Renilla luciferase expressing plasmid (pRL: Promega), thelatter of which was to normalize for transfection efficiency betweenwells, into HEK293T cells using Fugene according to manufacturer's(Roche Applied Sciences) protocol. Cells were cultured for 48 hrs andDual Luciferase assays performed according to manufacturer's (Promega)protocol using a Turner Biosystems Veritas luminometer.

Results of typical experiments are shown in FIG. 4A. These data showedthat all 10 ddRNAi constructs showed significant silencing of theantisense target, but differed significantly in activity against thesense target, reflecting marked differences in RISC loading of passengerstrands between the different ddRNAi constructs. Based on these datamiRs-2, 5 and 8 were chosen for further analyses.

To confirm the activity of these constructs against native VEGF-A,HEK293T cells were co-transfected with an expression plasmid expressingVEGF-A protein along with expression constructs for miR-2, 5 and 8 usingFugene according to manufacturer's (Roche Applied Sciences) protocol.After 48 hrs RNA were isolated using a modified Trizol Protocol(Invitrogen). VEGF-A mRNA levels were determined using RT QPCR Assay onDemand according to manufacturer's protocol (Applied Biosystems Inc).These data (FIG. 4B) show that VEGF-A shMiRs 2, 5 and 8 significantlyreduce steady state VEGF-A mRNA levels in the transfected cells.

To further validate the activity of shMiR-8 against endogenouslyexpressed VEGF-A, a spontaneously arising retinal pigment epithelia(RPE) cell line termed ARPE-19 were transduced with an adenovirusconstruct (MOI=200) that expresses miR-8. RNA and protein were isolatedfrom cells at 24, 48, 72 and 96 hrs. VEGF-A mRNA levels were determinedusing RTQPCR as described above. Protein levels were determined using anELISA assay performed with the Human VEGF Quantikine ELISA Kit accordingto manufacturer's (R&D Systems) protocol. These data (FIG. 4C) showedthat miR-8 potently silences VEGF-A expression at both the protein andmRNA level, with levels of knockdown increasing over time.

To quantify levels of shRNA expression from miR-8, a custom RT-QPCRassay was developed. A synthetic RNA standard (Sigma Aldrich) andforward DNA primers (Sigma Aldrich) were used to develop this assay inorder to quantify the levels of effector RNA processed from theexpressed shRNA of miR-8. The sequences of the synthetic RNA standardand DNA primers were:

Synthetic RNA standard: (SEQ ID NO: 130) UGGGUUAUGUGGGUGGGUGUGUCUACCGCCUForward primer (DNA): (SEQ ID NO: 131) TATGTGGGTGGGTGTGTCTAC

-   -   Reverse primer (DNA): miScript Universal Primer from kit        (Qiagen)

RNAs were reverse transcribed using the miSCRIPT Reverse TranscriptionKit according to manufacturer's protocol (Qiagen). Components of thiskit polyadenylate RNAs and synthesise cDNA copies via the actions ofreverse transcriptase and a clamped oligo dT primer which acts as aprimer for cDNA synthesis. cDNAs were amplified and quantified usingSYBR green QRT PCR assays, using protocols well known to those familiarwith the art. Known amounts of the synthetic RNA standard were reversetranscribed and QPCR amplified to prepare a standard curve. RNAs wereisolated from the aforementioned ARPE-19 cells and levels of expressedshRNA were quantified using this assay. FIG. 4B shows that the levels ofprocessed shRNA expressed form miR-8 increased over time and correlatedwith levels of VEGF-A knockdown at the protein and RNA level. Taketogether these data showed that miR-8 potently silenced VEGF-A. Notethat the VEGF-A target sequences and effector sequences of miRs-2, 5 and8 show absolute conservation of nucleotide sequences between human andthe pre-clinical test species mouse and macaque.

3. Design and Preparation of Constructs to Silence VEGFR2

ddRNAi constructs expressing shRNAs targeting VEGFR2 were designed,using the criteria described above, to recognise target sequences inVEGFR2 mRNA that are conserved between human and the pre-clinical testspecies mouse and macaque. In most cases, it was difficult to findsequences that were absolutely conserved between human, mouse and monkeyspecies. 10 ddRNAi constructs (miR-V-1, miR-V-2, miR-V-3, miR-V-4,miR-V-5, miR-V-6, miR-V-7, miR-V-8, miR-V-9 and miR-V-10) wereconstructed. Sequences of the BamHI/HindIII fragments used to preparethese are listed as SEQ ID NOS: 101-110 as summarised in Table 2.Inserts were cloned into pSilencer 2.1-U6 hygro as described in Example1.

4. Activity and Strand-Specificity of Constructs Targeting VEGFR2

Dual luciferase assays were performed as described above to determinethe activity and strand-preference of miR-V-1 through miR-V-10 using theprotocol described in Example 2 and the reporter constructs listed inTable 3.

TABLE 3 Reporter constructs used to assay activity and strandspecificity of miR constructs. Target Reporter gene GB Accessioncode^(a) Positions^(b) miR^(c) VEGF-A NM_001025366 A-sense  727-1221miR-2 (SEQ ID NO: 79) B-sense 1077-1829 miR-3, 4 & 5 C-sense 1715-2357miR-6, 7 & 8 D-sense 3149-3614 miR-9 & 10 E-sense 299-366 miR-1A-antisense  727-1221 miR-2 B-antisense 1077-1829 miR-3, 4 & 5C-antisense 1715-2357 miR-6, 7 & 8 D-antisense 3149-3608 miR-9 & 10E-antisense 299-366 miR-1 PDGFR-B NM_002609 A-sense  843-1340 miR-P-1, 2(SEQ ID NO: 85) B-sense 1920-2435 miR-P-3 C-sense 2672-3212 miR-P-4, 5,6, 7, 8 & 9 D-sense 2872-3421 miR-P-4, 5, 6, 7, 8, 9 & 10 A-antisense 843-1340 miR-P-1, 2 B-antisense 1920-2435 miR-P-3 C-antisense 2672-3212miR-P-4, 5, 6, 7, 8 & 9 D-antisense 2872-3421 miR-P-4, 5, 6, 7, 8, 9 &10 VEGFR-2 NM_002253 A-sense  382-1098 miR-V1, 2 (SEQ ID NO: 82) B-sense2519-3098 miR-V-3, 4, & 5 C-sense 3078-3567 mir-V-6, 7 & 8 D-sense3549-4108 mir-V-9 & 10 A-antisense  382-1098 miR-V1, 2 B-antisense2520-3098 miR-V-3, 4, & 5 C-antisense 3078-3567 mir-V-6, 7 & 8D-antisense 3549-4108 mir-V-9 & 10 CFB NM_001710 A-sense  739-1261miR-C-1, 2, (SEQ ID NO: 88) 3 & 4 B-sense 1361-1901 miR-C-, 5, 6 & 7C-sense 2008-2568 miR-C-8 & 9 A-antisense  739-1261 miR-C-1, 2, 3 & 4B-antisense 1361-1901 miR-C-5, 6 & 7 C-antisense 2008-2568 miR-C-8 & 9^(a)Code describing the particular luc fusion construct used in dualluciferase assays to assay the activity and strand specificity of miRconstructs. ^(b)Sequences included in luc fusion contructs. ^(c)miRconstructs assayed with individual reporters.

Results of these experiments are shown in FIG. 5A. These data showedthat all 10 constructs could achieve significant silencing of theantisense reporter construct but differed significantly in activityagainst the sense reporter construct, reflecting marked differences inRISC loading of passenger strands between the different ddRNAiconstructs and the resulting consequent propensities for off-targeteffects. Based on these data, miR-V-2, -3, -7 and -10 were chosen forsubsequent analyses.

To confirm the activity of these constructs against native VEGFR2 mRNA,HEK 293T cells were co-transfected with plasmids expressing VEGFR2miRs-V-2, 3, 7 and 10 and an expression plasmid expressing the fulllength cDNA for VEGFR2 using Fugene according to manufacturer's (RocheApplied Sciences) protocol. After 72 hours RNA were isolated asdescribed above. VEGFR2 mRNA levels were determined using a RT QPCR“Assay on Demand” according to manufacturer's protocol. These data (FIG.5B) showed that miRs-V-2, 3, 7 and 10 significantly reduced steady stateVEGFR2 mRNA levels compared to controls. FIG. 5C shows that miRs-V-2, 3,7 and 10 also strongly reduced VEGFR2 protein levels in parallel wellsof transfected cells as assessed by Western blot analysis. Take togetherthese data showed that miRs-V-2, 3, 7 and 10 potently silenced VEGFR-2.

5. Design and Preparation of Constructs to Silence PDGFR-β

ddRNAi constructs expressing shRNAs targeting PDGFR-β were designed,using the criteria described above, to recognise target sequences inPDGFR-β mRNA that are well conserved between human and the pre-clinicaltest species mouse and macaque. In most cases, there is a singlenucleotide mismatch between the human sequence and the correspondingsequences in both the mouse and monkey models. 10 ddRNAi constructs(miR-P-1, miR-P-2, miR-P-3, miR-P-4, miR-P-5, miR-P-6, miR-P-7, miR-P-8,miR-P-9 and miR-P-10) were made. Sequences of the BamHI/HindIIIfragments used to prepare these are listed as SEQ ID NOS: 111-120 assummarised in Table 2. Inserts were cloned into pSilencer 2.1-U6 hygroas described in Example 1.

6. Activity and Strand-Specificity of Constructs Targeting PDGFR-β

Dual luciferase assays were performed as described above and used todetermine the activity and strand preference of miR-P-1 through miR-10using the protocol described in Example 2 with the reporter constructslisted in Table 3. These data showed that all 10 constructs showedsignificant silencing of the antisense reporter construct. Based onthese data miR-P-4 and miR-P-9 were chosen for subsequent analyses.

To confirm the activity of these constructs against native PDGFR-β mRNA,HEK 293T cells were co-transfected with plasmids expressing eitherPDGFR-β miRs-P-4 or miR-P-9 and a plasmid expressing a full length cDNAof PDGFR-β using Fugene according to manufacturer's (Roche AppliedSciences). After 48 hours RNA was isolated as described above. PDGFR-βmRNA levels were determined using a RT QPCR “Assay on Demand” accordingto manufacturer's protocol. These data (FIG. 6A) showed that miRs-P-4and miR-P-9 significantly reduced steady state PDGFR-β mRNA levelscompared to controls. FIG. 6B shows that miR-P-4 and miR-P-9 alsostrongly reduced PDGFR-β protein levels in parallel transfected wells ofcells as compared to controls. Take together these data showed thatmiR-P-4 and miR-P-9 potently silenced PDGFR-β.

7. Design and Preparation of Constructs to Silence CFB

ddRNAi constructs expressing shRNAs that target CFB were designed, usingthe criteria described above, to recognise target sequences in CFB mRNAthat are conserved between human and the pre-clinical test species mouseand macaque. In most cases, there is either a single nucleotide mismatchor multiple mismatches between the human sequence and the correspondingsequences in both the mouse and monkey models. 9 ddRNAi constructs(miR-C-1, miR-C-2, miR-C-3, miR-C-4, miR-C-5, miR-C-6, miR-C-7, miR-C-8and miR-C-9) were made. Sequences of the BamHI/HindIII fragments used toprepare these are listed as SEQ ID NOS: 121-129 as summarised in Table2. Inserts were cloned into pSilencer 2.1-U6 hygro as described inExample 1.

8. Activity and Strand-Specificity of Constructs Targeting CFB

Dual luciferase assays were used as described above to determine theactivity and strand preference of miRs-C-1 to 9 using the protocoldescribed in Example 2 with the reporter constructs listed in Table 3.Results of these experiments are shown in FIG. 7A. These data showedthat most of the constructs showed significant silencing of theantisense reporter construct, but differed significantly in activityagainst the sense reporter construct, reflecting marked differences inRISC loading of passenger strands between the different ddRNAiconstructs and consequent potential for off-target effects. Based onthese data miR-C-1, miR-C-8 and miR-C-9 were chosen for subsequentanalyses.

To confirm the activity of these constructs against native CFB mRNA, HEK293T cells were co-transfected with plasmids expressing either miRs-C-1,miR-C-8 or miR-C-9 and a plasmid expressing the full length cDNA for CFBusing the above mentioned methods. After 48 hours RNA was harvested andCFB mRNA levels were determined using a RT QPCR “Assay on Demand”. Thesedata (FIG. 7B) showed that miR-C-1, miR-C-8 and miR-C-9 significantlyreduced steady state CFB mRNA levels compared to control treated cells.FIG. 7C shows that miRs-C-1, miR-C-8 or miR-C-9 also strongly reducedCFB protein levels parallel transfected cells as compared to controls.As determined by western blot analysis. Taken together these data showedthat miRs-C-1, miR-C-8 and miR-C-9 potently silenced CFB.

9. Constructs Targeting VEGF-A

Constructs designed to express therapeutic miR-based shRNAs targetingVEGF-A were prepared. These used either the U6 promoter which wouldexpress shRNAs in all cells, or one of four tissue-specific promoterswhich would express therapeutic shRNAs in appropriate cells. The fourtissues-specific promoters were human VDM2 promoter, human ICAM2promoter, human RPE65 promoter and human FLT promoter.

DNA fragments were synthesised (Blue Herron) that consisted of promotersequences fused to the miR-7 sequences described in FIG. 2C. Thesefragments contained flanking restriction sites to allow cloning into AAVvectors; for constructs using pol II promoters the AAV vectors containeda minimal polyadenylation site to ensure appropriate transcriptionaltermination. Maps of these fragments are shown in FIG. 9 and are listedas SEQ ID NOS: 132 through to SEQ ID NOS: 136.

10. Constructs Targeting VEGF-A and VEGFR2

Constructs designed to express therapeutic miR-based shRNAs targetingVEGFF-A and VEGFR2 were prepared. These used either the U6 promoterwhich would express shRNAs in all cells, or one of the fourtissue-specific promoters in Example 9.

DNA fragments were synthesised (Blue Herron) that consisted of promotersequences fused to the miR-7-miR-V-7 sequences and contained flankingrestriction sites to allow cloning into AAV vectors as described inExample 9. Maps of these fragments are shown in FIG. 10 and are listedas SEQ ID NOS: 137 through to SEQ ID NOS: 141.

11. Constructs Targeting VEGFR2, PDGFR-β and CFB

Constructs designed to express therapeutic miR-based shRNAs targetingVEGFR2, PDGFR-β and CFB were prepared. These used either the U6 promoterwhich would express shRNAs in all cells, or one of the fourtissue-specific promoters in Example 9. Each of the hairpins from singleconstructs miR-V-7, miR-C-8 and miR-P-9 sequences were subcloned into asingle vector (in the same order) using a series of restriction enzymesthat were engineered into the single vectors. The resultant expressionconstruct also contained flanking restriction sites to allow cloninginto AAV vectors as described in Example 9. Promoters reduced topractice used for the expression of these constructs included the humanU6 promoter, the FLT promoter, and the ICAM2 promoter which wereindependently synthesized at Blue Heron. Each of the constructs producedwere sequence verified prior to use. Maps of these fragments are shownin FIG. 11 and are listed as SEQ ID NOS: 142 through to SEQ ID NOS: 146.

REFERENCES

-   Anderson et al, 2010. Prog Retin Eye Res. 29: 95-112.-   Ashfield et al., 1994. EMBO J Vol113 No 23 5656 Boye et al, 2012.    Human Gene Ther 23:1101-1115.-   Dalkara, D et al. 2013. Science Translational Medicine, 5:189ra76-   Gregory et al., 2005. Cell 18: 631-640-   Gu et al, 2012. Cell 151: 900-911.-   Frank et al., 2010. Nature. 465:818-22-   Gabriel N et al. 2013. Hum Gene Ther Methods. (2):80-93)-   Kleinman et al., 2008. Nature 452: 591-7-   Maraia et al. 1994. Nucl Acids Res. 22: 3045-3053-   McBride et al, 2008. PNAS 105:5868-5873.-   Nguyen et al. Ophthalmology. 2012 September; 119(9):1867-73.-   Petrs-Silva et al. 2009. Mol Ther. 17(3): 463-471-   Schwarz et al., 2003. Cell 115: 199-208-   Stewart M W. Br J Ophthalmol (2012).    doi:10.1136/bjophthalmol-2011-300654-   Wasworth et al. Molecular Therapy vol. 19 no. 2 Feb. 2011; 326-334-   Wu et al 2011. PLoS ONE 6:e28580-   Yonaha and Proudfoot, 2000. EMBO J. 19:3770-3777-   Zhong et al. 2008. Proc Nat Acad Sci USA. 105(22): 7827-7832-   Zhu et al, 2010. Adv Exp Med Biol 664: 211-216.-   U.S. Pat. No. 6,573,099-   US 2002/162126 U.S. Pat. No. 6,218,181-   WO1999/49020-   WO2003/022052

1. A DNA-directed RNA interference (ddRNAi) agent for inhibitingexpression of one or more target sequences in an AMD associated gene,the ddRNAi agent comprising: a first effector sequence of at least 17nucleotides in length; and a first effector complement sequence; whereinthe effector sequence is substantially complementary to one or moretarget regions in a transcript of the one or more target sequences.
 2. AddRNAi agent according to claim 1, comprising a second effector sequenceand second effector complement sequence.
 3. A ddRNAi agent according toclaim 2 comprising, in a 5′ to 3′ direction: (a) a first effectorsequence of at least 17 nucleotides in length; a second effectorsequence of at least 17 nucleotides in length; a second effectorcomplement sequence; and a first effector complement sequence; or (b) afirst effector sequence of at least 17 nucleotides in length; a firsteffector complement sequence; a second effector sequence of at least 17nucleotides in length; and a second effector complement sequence;wherein each effector sequence is substantially complementary to one ormore target regions in a transcript of the one or more target sequences.4. (canceled)
 5. A ddRNAi agent according to claim 1, wherein: (i) theAMD associated gene is selected from the group consisting of VEGF-A,VEGFR2, PDGFR-β and CFB; (ii) the target sequences are selected from thegroup consisting of any 10 or more contiguous nucleotides within asequence set forth in any one of SEQ ID NOS: 1-39; (iii) the AMDassociated gene is VEGF-A and each effector sequence is selected fromthe sequences set forth in SEQ ID NOS: 40-49; (iv) the AMD associatedgene is VEGFR2, and each effector sequence is selected from thesequences set forth in SEQ ID NOS: 50-59; (v) the AMD associated gene isPDGFR-β and each effector sequence is selected from the sequences setforth in SEQ ID NOS: 60-69; or (vi) the AMD associated gene is CFB andeach effector sequence is selected from the sequences set forth in SEQID NOS: 70-78. 6-10. (canceled)
 11. A ddRNAi agent according to claim 1,wherein the agent is expressed within a miRNA structure.
 12. A ddRNAiagent according to claim 1, wherein the AMD is wet AMD.
 13. A ddRNAiexpression cassette for expressing a ddRNAi agent according to claim 1,the expression cassette comprising (in no particular order): one or morepromoter sequences; one or more DNA sequences that encode for one ormore effector sequences; and one or more DNA sequences that encode forone or more effector complement sequences; and optionally: one or moreterminator sequences; one or more DNA sequences that encode for loopsequences, spacer sequences, or both; one or more enhancer sequences;and/or miRNA encoding (ME) sequences.
 14. (canceled)
 15. A ddRNAiexpression construct comprising a ddRNAi expression cassette accordingto claim
 13. 16. A ddRNAi expression construct according to claim 15,wherein the construct is a viral delivery construct.
 17. A method oftreating AMD in a subject comprising administering a therapeuticallyeffective amount of a ddRNAi expression construct of claim 15,optionally wherein the AMD is wet AMD.
 18. (canceled)
 19. A method oftreating choroidal neovascularisation in a subject comprisingadministering a therapeutically effective amount of a ddRNAi expressionconstruct of claim
 15. 20. A method of reducing drusen deposits in asubject comprising administering a therapeutically effective amount of addRNAi expression construct of claim
 15. 21. A method according to claim17, wherein the ddRNAi expression construct is administered to thesubject's eye/s by intravitreal injection.
 22. A pharmaceuticalcomposition comprising a ddRNAi expression construct of claim 15, and apharmaceutically acceptable carrier or diluent.
 23. A ddRNAi agentaccording to claim 2, wherein: (i) the AMD associated gene is selectedfrom the group consisting of VEGF-A, VEGFR2, PDGFR-β and CFB; (ii) thetarget sequences are selected from the group consisting of any 10 ormore contiguous nucleotides within a sequence set forth in any one ofSEQ ID NOS: 1-39; (iii) the AMD associated gene is VEGF-A and eacheffector sequence is selected from the sequences set forth in SEQ IDNOS: 40-49; (iv) the AMD associated gene is VEGFR2, and each effectorsequence is selected from the sequences set forth in SEQ ID NOS: 50-59;(v) the AMD associated gene is PDGFR-β and each effector sequence isselected from the sequences set forth in SEQ ID NOS: 60-69; or (vi) theAMD associated gene is CFB and each effector sequence is selected fromthe sequences set forth in SEQ ID NOS: 70-78.
 24. A ddRNAi expressioncassette for expressing a ddRNAi agent according to claim 2, theexpression cassette comprising (in no particular order): one or morepromoter sequences; one or more DNA sequences that encode for one ormore effector sequences; and one or more DNA sequences that encode forone or more effector complement sequences; and optionally: one or moreterminator sequences; one or more DNA sequences that encode for loopsequences, spacer sequences, or both; one or more enhancer sequences;and/or miRNA encoding (ME) sequences.
 25. A ddRNAi expression constructcomprising a ddRNAi expression cassette according to claim 24,optionally comprising miRNA encoding (ME) sequences.
 26. A ddRNAiexpression construct according to claim 25, wherein the construct is aviral delivery construct.
 27. A method of treating AMD in a subjectcomprising administering a therapeutically effective amount of a ddRNAiexpression construct of claim
 25. 28. A method according to claim 27wherein the AMD is wet AMD.
 29. A method of treating choroidalneovascularisation in a subject comprising administering atherapeutically effective amount of a ddRNAi expression construct ofclaim
 25. 30. A method of reducing drusen deposits in a subjectcomprising administering a therapeutically effective amount of a ddRNAiexpression construct of claim
 25. 31. A method according to claim 27,wherein the ddRNAi expression construct is administered to the subject'seye/s by intravitreal injection.
 32. A pharmaceutical compositioncomprising a ddRNAi expression construct of claim 25, and apharmaceutically acceptable carrier or diluent.